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SUMMARY 
 I
SUMMARY (German) 
Die beständige Autoantikörperproduktion in Patienten mit Systemischem Lu-
pus Erythematodes (SLE) suggeriert die Existenz eines autoreaktiven humoralen 
Gedächtnisses; die Häufigkeit selbstreaktiver Gedächtnis-B-Zellen in SLE wurde je-
doch noch nicht ermittelt. Unter normalen Umständen exprimieren neu gebildete B-
Zellen im Knochenmark Autoantikörper mit hoher Frequenz, darunter auch antinukle-
äre Antikörper. Diese autoreaktiven B Zellen unterliegen, bevor sie zu naiven immun-
kompeten Zellen heranreifen, einer strengen Überwachung an zwei Kontrollpunkten 
für Selbsttoleranz, einer im Knochenmark und einer in der Peripherie. Im Gegensatz 
dazu steht SLE mit einem Defekt in Zusammenhang, der die Etablierung von B-Zell-
Toleranz an diesen beiden Kontrollpunkten verhindert. Die Folge ist eine hohe Anzahl 
selbstreaktiver naiver B-Zellen in der Peripherie. 
Das Ziel dieser Studie war die Bestimmung der molekularen Eigenschaften 
und Reaktivitäten von IgG Gedächtnis-B-Zell-Antikörpern in SLE. Mit Hilfe einer auf 
einer Einzelzell-PCR basierenden Methode wurden 200 monoklonale Antikörper von 
einzelnen IgG+ Gedächtnis-B-Zellen von vier unbehandelten SLE Patienten kloniert. 
Die generelle Häufigkeit an polyreaktiven und HEp-2 selbstreaktiven Antikörpern in 
dieser Population war vergleichbar mit der in gesunden Vergleichspersonen. 15% der 
Antikörper aus IgG+ Gedächtnis-B-Zellen eines Patienten mit Serum-
Autoantikörpertitern derselben Spezifität waren hochreaktiv und spezifisch gegen die 
SLE-assoziierten löslichen Kernantigene Ro52 und La. Dies war jedoch nicht der Fall 
in den übrigen drei Patienten oder gesunden Vergleichspersonen. Die Keimbahnkon-
figurationen dieser Antikörper gegen lösliches Kernantigen waren nicht-selbstreaktiv 
oder polyreaktiv mit schwacher Ro52-Bindung und untermauern somit die Theorie, 
dass somatische Mutationen zur Reaktivität und Spezifität von Autoantikörpern bei-
tragen. Die Varianz der Häufigkeit, mit der Gedächtnis-B-Zellen SLE-assoziierte Anti-
körper exprimieren, legt nahe, dass dies eine wichtig Variable für den Erfolg von The-
rapien sein kann, die diese Population beseitigen. 
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SUMMARY (English) 
Persistent autoantibody production in patients with systemic lupus erythema-
tosus (SLE) suggests the existence of autoreactive humoral immunological memory, 
but the frequency of self-reactive memory B cells in SLE has not been determined. 
Under normal circumstances, autoantibodies including antinuclear antibodies (ANAs) 
are frequently expressed by newly generated B cells in the bone marrow, but these 
autoreactive B cells are tightly regulated at two checkpoints for self-tolerance, in the 
bone marrow and the periphery, before maturation into naïve immunocompetent B 
cells. In contrast, SLE is associated with a failure to establish B cell tolerance at the 
two checkpoints leading to high numbers of autoreactive naïve B cells in the periph-
ery.  
The aim of this study was to determine the molecular features and reactivities 
of IgG memory B cell antibodies expressed in SLE. A single-cell PCR based strategy 
was applied that allowed the cloning of the Ig heavy and Ig light chain genes of a sin-
gle purified B cell and the in vitro expression of 200 recombinant monoclonal antibod-
ies from single IgG+ memory B cells of four untreated SLE patients. The overall fre-
quency of polyreactive and HEp-2 self-reactive antibodies in this compartment was 
similar to healthy controls (HC). 15% of IgG memory B cell antibodies were highly 
reactive and specific for SLE-associated extractable nuclear antigens (ENAs) Ro52 
and La in one patient with serum autoantibody titers of the same specificity but not in 
the other three patients or healthy individuals. The germline forms of the ENA anti-
bodies were non-self-reactive or polyreactive with low binding to Ro52 supporting the 
idea that somatic mutations contribute to autoantibody specificity and reactivity. Het-
erogeneity in the frequency of memory B cells expressing SLE-associated autoanti-
bodies suggests that this variable may be important in the outcome of therapies that 
ablate this compartment. 
 
Autoimmunität, SLE, Gedächtnis, Antikörper, Selbstreaktivität 
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aa amino acid 
ABTS 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) 
AID activation-induced cytidine deaminase 
ANA antinuclear antibody 
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D diversity 
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FITC fluorescein isothiocyanate 
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GC germinal center 
H heavy 
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HEK human embryonic kidney 
HRP horseradish peroxidase 
IFA indirect fluorescent assay 
Ig Immunoglobulin 
J joining 
L light 
LB Lysogeny broth 
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LPS lipopolysaccharide 
MHC major histocompatibility complex 
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RNP ribonuclear protein 
RT reverse transcriptase 
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1 INTRODUCTION 
 
1.1 The immune system 
The immune system protects multicellular organisms from the invasion of for-
eign particles and the reproduction of potentially harmful microbes. In vertebrates, it 
is a highly interactive network, which constitutes of the innate and the adaptive 
branch. The prevailing property of the innate immunity is to recognize conserved 
structures expressed by foreign organisms, such as lipopolysaccharides (LPS) on the 
outer bacterial membrane, and thus acts as a rather unspecific first line of defense 
(Akira, et al., 2006). If this immediate response fails, the adaptive immune system is 
activated in the form of lymphocytes, which derive from hematopoietic stem cells in 
the bone marrow. Whereas T cells provide cell-mediated immunity, B cells provide 
humoral immunity through the secretion of antibodies. Random genetic recombina-
tion and mutational processes enable the generation of high affinity receptors with 
specificities against any chemical structure, but delay the onset of response. Recog-
nition within the adaptive immune system is mediated by glycoproteins on the lym-
phocytes' surface, the B cell receptors (BCRs) and the T cell receptors, which belong 
to the immunoglobulin superfamily. 
 
1.2 Immunoglobulins 
In their basic structure, antibodies or immunoglobulins (Ig) are composed of 
two identical heavy (H) and light (L) chains, which are covalently connected by disul-
fide bonds to form a heterotetramer (Figure 1; (Davies, et al., 1975; Hill, et al., 1966)). 
Based on their amino acid (aa) sequences, the IgH and the two types of IgL chain, κ 
and λ, can be divided into a constant region towards the carboxy-terminal end and a 
variable region at the amino-terminal end of each chain. While the constant region 
determines the effector function, especially in the case of the heavy chain, the vari-
able region shapes the antibodies specificity and affinity at the antigen binding site 
(Kirkham and Schroeder, 1994). The structural backbone of the variable region is 
provided by the four frame work regions (FWR) 1, 2, 3, and 4. They are interspersed 
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by three segments referred to as hypervariable or complementarity determining re-
gions (CDRs) 1, 2, and 3, which are exposed as loops at the antigen-binding region 
(Capra and Kehoe, 1975). CDR3 is the most variable of the CDRs and has been as-
cribed a dominant role in determining the antibody's specificity (Parhami-Seren and 
Margolies, 1996). In their membrane bound form, the IgH chains possess a hydro-
phobic C-terminal region spanning the cell membrane and a short intracytoplasmic 
tail constituting the BCR together with the invariant Igα and Igβ chains. For the con-
stant region of the human IgH chain five different isotypes can be distinguished 
based on their aa sequence. While IgM and IgD are expressed on mature lympho-
cytes through alternative splicing, the expression of IgG, IgA, and IgE is achieved 
through an irreversible genetic rearrangement process, called class switch recombi-
nation (CSR). 
 
 
Figure 1: Schematic structure of an Immunoglobulin G. The Immunoglobulin (Ig) consists 
of two identical heavy (blue) and light (green) chains which are connected by disulfide bonds 
(black). Both heavy and light chains contain a variable (VH and VL, lighter color) and a con-
stant region (CH and CL, darker color). The V region is folded to expose the highly variable 
complementary determining regions (CDRs) 1, 2, and 3 (red, visualized at VL) at the antigen-
binding site. Papain digest cleaves the Ig into the Fc and the two Fab fragments determining 
the Igs biological function and its specificity, respectively (modified from (Janeway, et al., 
2008)). 
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1.3 Generation of immunoglobulin diversity 
The main requisite for the generation of an antigen-specific immune response 
is a genetic recombination process, which takes place in the bone marrow during 
early lymphocyte development, called V(D)J recombination. The gene loci for the 
IgH, the Igκ, and the Igλ L chain are located on different chromosomes, with the hu-
man IgH chain locus residing on chromosome 14, and differ slightly in their organiza-
tion (Croce, et al., 1979; Matsuda, et al., 1998). The variable region domain of the 
IgH chain is encoded by three different gene segment clusters, which are designated 
V (variable), D (diversity), and J (joining), followed by the constant region segments 
of the different Ig isotypes (Figure 2; (Brack, et al., 1978)). V, D, and J segments are 
not contiguous in their germline order and are recombined to generate expressable Ig 
genes, generally with the excision of the intervening DNA (Tonegawa, et al., 1978). 
Crucial for this process are two enzymes called RAG1 and 2 (from: recombination 
activating gene), which are expressed in developing lymphocytes and induce a dou-
ble strand break of the DNA, which enables the joining of the next gene segment 
(McBlane, et al., 1995; Mombaerts, et al., 1992; Schatz and Baltimore, 1988; Shinkai, 
et al., 1992). Rearrangement on the IgH chain locus involves two steps: The recom-
bination of a DH to a JH segment and the recombination of a VH gene segment to 
the DJH joint. Recombination signal sequences (RSSs), including conserved hep-
tamer and nonamer sequences at the end of each segment, ensure that V and J of 
the IgH chain are not joined directly (Ramsden, et al., 1996). Imprecisions of the join-
ing events lead to the deletion of nucleotides or the addition of untemplated N nucleo-
tides. The DH segment can therefore be joined in any of the three reading frames 
and an additional diversification of the Ig gene is created (Victor and Capra, 1994). 
As a consequence, BCRs can differ in their specificities even when utilizing the same 
gene segments. The process further accounts for the extreme variability of the CDR3 
which is located at the joining region of the V, D, and J segments. The gene loci of 
the Igκ and Igλ L chain of the BCR generally follow the same assembling process, 
though lacking D segments. Tolerance mechanism or the introduction of somatic mu-
tations during a T-cell dependent antigen-mediated immune response can lead to 
further diversification of the BCR (see below). 
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Figure 2: The V(D)J recombination. V(D)J recombination is depicted with a simplified ver-
sion of the heavy chain locus. Joining of one DH with one JH occurs first, with the excision of 
the intervening DNA, guided by recombination signal sequences (RSS) (orange and purple 
triangles), and followed by VH to DJH joining. The VDJ gene segment is spliced to Cμ and 
Cδ in pre-germinal center B cells and to either Cα, Cγ, or Cε after class switch recombination 
(here: CH, blue) (modified from (Janeway, et al., 2008)). 
 
1.4 Immunological memory and memory B cells 
Immunological memory describes the ability of the adaptive immune system to 
respond more rapidly and effectively to a secondary exposure with a previously en-
countered antigen (Steiner and Eisen, 1967). This accelerated response is provided 
by specifically reactive memory B and T cells, which possess intrinsic functionally 
differences from naïve cells and thus forms the basis for vaccination. Following anti-
gen-encounter, mature naïve B cells either directly differentiate into plasma cells 
(PCs) secreting low affinity antibodies or migrate into the germinal centers (GCs) to 
become high affinity memory B cells or plasma cells (Figure 3). GCs are specialized 
immunological microstructures in the spleen, tonsils, or lymph nodes, where activated 
B cells are brought into proximity with follicular dendritic cells and T helper cells, 
which present antigens and provide survival signals for B cells expressing higher af-
finity BCRs (Ahmed and Gray, 1996). Alteration of the BCR affinity is achieved 
through somatic mutations in the IgV gene segments which are randomly introduced 
by the RNA-editing enzyme activation-induced cytidine deaminase (AID) (Berek and 
Milstein, 1988). Beside the positive selection of B cells expressing high affinity recep-
tors, called affinity maturation, CSR of the IgH chain locus to IgG, IgA, or IgE enables 
a more distinct effector function of the secreted antibody while retaining its specificity. 
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Figure 3: Scheme of memory B cell and plasma cell generation. After antigen encounter 
mature naïve B cells either differentiate into low affinity antibody-secreting plasma cells or 
proceed to germinal centers where they can acquire somatic hypermutations (red stars) and 
undergo class switch recombination with the help of T cells. Follicular dendritic cells (FDC) 
provide further antigen stimuli. B cells further maturate into memory B cells or high affinity 
antibody-secreting plasma cells. 
 
Memory B cell specificities correlate with antibody serum titers (Bernasconi, et 
al., 2002), but the direct contribution of the memory B cell pool to antibodies in the 
serum remains a matter of debate. Protective memory is maintained without continu-
ous antigen-stimulation, and antigen-specific B cells and serum antibodies can be 
isolated more than 80 years after antigen encounter (Crotty, et al., 2003; Putz, et al., 
2005; Yu, et al., 2008). One possible explanation was provided by the discovery of 
the long-lived PCs (Manz, et al., 1997; Radbruch, et al., 2006; Slifka, et al., 1998), yet 
it remained questionable whether one cell could maintain serum titers for decades, 
even if retained in a specialized niche, which, until now, has not been identified. An-
other concept focuses on the maintenance of specificities by the slow division rate of 
memory B cells (Macallan, et al., 2005; Wirths and Lanzavecchia, 2005). Memory B 
cells further express a great number of Toll-like receptors (TLRs) and can easily be 
activated to differentiate into antibody-secreting PCs (Bernasconi, et al., 2003; Ber-
nasconi, et al., 2002), which could replace the long-lived PCs in their niches 
(Odendahl, et al., 2005). What favors the latter theory is the observation that anti-
body-titers of other memory specificities are elevated after a tetanus vaccine boost 
(Bernasconi, et al., 2002). This so called bystander activation nevertheless stresses 
INTRODUCTION 
 6
the possible downside of immunological memory. The beneficial effect that the pre-
vention of reinfection has for the host, could, in the case of autoimmune disorders, 
lead to the persistence of autoreactivity. 
 
1.5 Autoreactivity and tolerance 
The randomness of the V(D)J recombination that forms the basis for the gen-
eration of specificities against all kinds of antigens, eventually leads to the generation 
of potentially pathogenic autoreactive lymphocytes (Ignatowicz, et al., 1996; Laufer, 
et al., 1996; Wardemann, et al., 2003; Zerrahn, et al., 1997). Paul Ehrlich proposed 
that the consequences of the formationn of self-reactive specificities would be so se-
vere that the immune system strictly prohibited its occurrence (Silverstein, 2001). De 
facto, the immune system has the ability to distinguish between self and non-self 
within the healthy organism. Sequential developmental tolerance checkpoints deter-
mine cell fate and prevent the maturation of highly self-reactive lymphocytes. While T 
cell tolerance is established in the thymus (Kisielow, et al., 1988), B cells pass a 
number of tolerance checkpoints along maturation. Central B cell tolerance is estab-
lished in the bone marrow, where strongly autoreactive B cells are prevented from 
proceeding into the immature B cell stage at the first tolerance checkpoint by one or 
more of the following three mechanisms: deletion, anergy, and receptor editing (Gay, 
et al., 1993; Goodnow, et al., 1988; Nemazee and Buerki, 1989; Radic, et al., 1993; 
Tiegs, et al., 1993). While clonal deletion has been defined as self-antigen induced 
apoptosis of autoreactive B cells (Nemazee and Buerki, 1989), anergy leaves low-
affinity self-reactive B cells unresponsive to further antigenic stimulation, but allows 
them to leave the bone marrow (Goodnow, et al., 1988; Nossal and Pike, 1980). Re-
ceptor editing enables B cells to reduce their self-reactivity by secondary recombina-
tion, predominantly at the IgL chain locus of the BCR (Gay, et al., 1993; Radic, et al., 
1993; Tiegs, et al., 1993) and has been estimated to be the dominant mechanism in 
establishing self tolerance under physiological conditions (Casellas, et al., 2001; 
Halverson, et al., 2004; Retter and Nemazee, 1998). Nevertheless, this negative se-
lection of autoreactive B cells can be bypassed. The autoantibody-encoding genes 
are not always inactivated in every autoreactive cell, causing allelic inclusion and the 
expression of BCRs with dual specificities. As a consequence, potentially pathogenic 
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self-reactive B cells can participate normally in immune reactions (Casellas, et al., 
2007). Peripheral tolerance mechanisms in humans are less well defined but contrib-
ute to the further exclusion of self-reactive B cells in becoming fully mature 
(Wardemann, et al., 2003). A third checkpoint was identified on B cell progression 
into the IgM memory B cell compartment (Tsuiji, et al., 2006). IgG memory B cells 
exhibit elevated levels of self- and polyreactivity as compared to their immediate pre-
cursors, the mature naïve B cells, thus contradicting the idea of a further tolerance 
checkpoint. Yet, it can not be excluded that the progression of high affinity autoreac-
tive B cells into the IgG memory B cell compartment, generated as a byproduct of the 
GC reaction, is prevented in healthy humans (Tiller, et al., 2007). Intermediate levels 
of polyreactivity have been found to occur frequently and spontaneously, even before 
any immune response has taken place within the organism (Ochsenbein, et al., 1999; 
Ochsenbein and Zinkernagel, 2000; Tiller, et al., 2007). These specificities have thus 
been termed natural antibodies, and it was suggested that their presence would be 
favorable in providing a rather unspecific but fast resistance against infections. As a 
consequence, it was concluded that it is more likely a matter of high frequency and 
reactivity than the mere presence of autoantibodies that lead to autoimmune disor-
ders. 
 
1.6 Autoimmunity 
Defects in the establishment of tolerance enable self-reactive lymphocytes to 
mount immune responses against structures normally present in the host. Clinical 
manifestations can occur either organ-specific or systematically and often include the 
destruction of tissue through inflammatory processes (Davidson and Diamond, 2001). 
While the restriction towards certain tissues is believed to result from a limited set of 
autoantigens or cross-reactive specificities against exogenous antigens, systemic 
diseases are thought to emerge from a more global deregulation of the immune sys-
tem. Systemic autoimmune diseases are mostly based on a multigenic predisposition 
in combination with environmental triggers, and women are generally more suscepti-
ble than men (Zandman-Goddard, et al., 2007). Alleles associated with autoimmunity 
effect general mechanisms such as antigen presentation, cytokine production, lym-
phocyte signaling, and apoptosis. Therefore, the genetic background predisposes to 
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more than a single autoimmune disease and increases the risk of developing multiple 
or overlapping manifestations. Microbial infections are regarded as an important trig-
ger, for example, through the polyclonal activation of autoreactive cells or the genera-
tion of cross-reactive specificities that also recognize self (Bernasconi, et al., 2002; 
McClain, et al., 2005). Despite the overwhelming data on the presence of autoanti-
bodies in many autoimmune diseases, their definite role in pathogenesis remains 
elusive. Since the exact cause of many autoimmune diseases has not been identi-
fied, therapeutic strategies focus on symptomatic treatment in addition to broadly act-
ing immunosuppressive agents. 
 
1.7 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune 
disease that is characterized by a loss of self-tolerance against nuclear and cyto-
plasmic antigens (Kotzin, 1996). Its clinical manifestations are extremely variable and 
diverse and can affect the connective tissue of the whole body involving skin, joints, 
kidneys, and the nervous system. Disease severity has a tendency to fluctuate over 
time, and common symptoms include skin rashes, joint pain, and fever (Vitali, et al., 
1992). SLE occurs mainly in women of childbearing age and is more frequent among 
people of Asian and African descent (Kotzin, 1996; Whitacre, 2001). Diagnosis is 
usually based on a catalog from the American College of Rheumatology consisting of 
11 criteria, of which four should be fulfilled. Genetic susceptibility predisposes for dis-
ease onset, but environmental factors, such as exposure to chemicals and sunlight or 
viral and bacterial infections, can exacerbate the disease and trigger flares (Kotzin, 
1996). A hallmark of the disease is high serum titers of anti-nuclear autoantibodies of 
the IgG isotype, which are present in the sera of patients long before disease onset 
(Arbuckle, et al., 2003). More than 100 specificities of autoantibodies have been iden-
tified (Sherer, et al., 2004), which are believed to participate directly or indirectly in 
SLE pathogenesis, for example through the formation of immunocomplexes and the 
deposition in organs, where they cause inflammation and tissue destruction 
(Davidson and Diamond, 2001; Koffler, et al., 1974; Kotzin, 1996; Sherer, et al., 
2004). SLE has been associated with increased apoptosis and a clearance defect of 
apoptotic cell material (Gaipl, et al., 2007), and an early breakdown in B cell toler-
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ance at the first two checkpoints in SLE leads to an increase of autoreactive mature 
naïve B cells in the periphery (Yurasov, et al., 2006; Yurasov, et al., 2005). Conceiv-
able causes are a diverted cytokine milieu and defective cellular regulatory mecha-
nisms (Lipsky, 2001). The increased presence of autoantigens and the multivalency 
of immunocomplexes provide a possible source for the activation of autoreactive cells 
and thus facilitate the generation of highly specific autoantibodies (Kotzin, 1996; Tay-
lor, et al., 2000). Certain SLE-associated autoantibodies have further been identified 
to be highly reactive against exogenous antigens, such as Ebstein-Barr virus surface 
protein (James, et al., 2001; McClain, et al., 2005). Somaticly mutated anti-DNA anti-
bodies in SLE suggest an active selection for autoantigen specificity (van Es, et al., 
1991). Anti-dsDNA autoantibodies appear fairly early and titers correlate with disease 
activity (Hahn, 1998). Antibodies against the extractable nuclear antigens (ENAs) Ro 
and La play a role in skin involvement and congenital heart block in infants of serum 
positive mothers (Buyon, et al., 1998; Dorner, et al., 2000; Salomonsson, et al., 2005; 
Wahren-Herlenius and Sonesson, 2006). Standard treatment of SLE involves the 
administration of non-glucocorticoid immunosuppressive drugs and goes as far as B 
cell depletion therapy and autologous hematopoietic stem cell transplantation for se-
verer cases. 
 
1.8 The role of B and T cells in SLE 
B cells are regarded as the main cause in SLE pathogenesis. Besides their 
role in the production of autoantibodies, B cells function as antigen presenters and 
provide immunoregulatory control of T cells, dendritic cells, and other B cells, partially 
through the production of cytokines (Chan, et al., 1999; Lipsky, 2001; Vallerskog, et 
al., 2007). The most direct evidence for the role of B cells comes from B cell ablative 
therapies with the chimeric human-specific anti-CD20 antibody Rituximab, which 
proves to be effective (Garcia-Carrasco, et al., 2009). CD20 is a B cell specific sur-
face molecule and expressed at most stages of development. Rituximab was origi-
nally developed for the treatment of lymphomas and ablates B cells by complement-
dependent cytotoxicity and antibody-mediated cell-dependent cytotoxicity (Reff, et al., 
1994). The role of T cells in SLE pathogenicity is less well defined. Yet, they mediate 
Ig isotype class switching, somatic mutations, and affinity maturation within the proc-
INTRODUCTION 
 10
ess of autoantibody production. In mice, interference in B and T cell interaction leads 
to disease improvement (Finck, et al., 1994; Mohan, et al., 1995). The enhanced 
susceptibility of carriers of particular class II major histocompatibility complex (MHC) 
alleles to SLE further supports the presence of autoreactive T cells in SLE (Kotzin, 
1996). In addition, cytokine production of T cells contributes to the overactivation of 
the immune system (Morimoto, et al., 2007). 
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AIM 
The aim of this study was to determine the frequency of self-reactivity in pe-
ripheral IgG+ memory B cells of SLE patients and to further characterize the molecu-
lar features of this compartment. For this, the antibodies of peripheral circulating IgG+ 
memory B cells from four untreated SLE patients were cloned, their DNA sequences 
analyzed, and tested in numerous reactivity assays. To determine the origin of soma-
tically mutated SLE-specific autoantibodies cloned from the IgG+ memory B cells of 
one SLE patient, they were reverted together with a number of randomly selected 
antibodies from all SLE patients to their germ-line configuration and their reactivity 
compared to the mutated counterparts. 
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2 METHODS 
 
For a detailed list of materials and equipments applied refer to supplemental 
materials 
 
2.1 Production of monoclonal antibodies from single B cells 
 
 
Figure 4: Strategy outline for the generation of recombinant antibodies from single B 
cells. IgG+ memory B cells from peripheral blood are stained according to surface markers 
and single-cell FACS sorted into 96-well plates. Following nested RT-PCR, IgH and IgL chain 
genes are sequenced and cloned into eukaryotic expression vectors before co-transfection 
into HEK 293 cells. Recombinant antibodies are harvested from supernatants and tested for 
reactivity in ELISA, IFA, and line immunoblot assay. 
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2.1.1 Isolation of single human peripheral blood B cells by fluores-
cence activated cell sorting 
All human samples were obtained after signed informed consent in accor-
dance with the institutional review board (IRB) reviewed protocols. Control data from 
IgG+ memory B cells of three additional healthy donors were previously published 
and are shown for comparison (Tiller, et al., 2008). Mononuclear cells were enriched 
from peripheral venous blood using RosetteSep® human B cell enrichment antibody 
cocktail (Stemcell Technologies Inc.) and purified by Ficoll-Paque® (GE Healthcare) 
density gradient centrifugation according to the manufacture’s instructions. 
Tetrameric RosetteSep antibodies cross-link undesired mononuclear blood cells to 
red blood cells (RBCs) by binding to specific surface markers. After an incubation 
step of 20 min at ambient temperature, these immunoprecipitates pelletize together 
with other unbound RBCs when centrifuged over a buoyant density medium, such as 
Ficoll. Purified mononuclear cells are harvested from the interface.  
CD19+CD38-CD27+IgG+ memory B cells and CD19+CD38+CD27+IgG+ plas-
mablasts were stained with anti-human antibodies CD19-allophycocyanin (APC), 
CD38-phycoerythrin (PE), CD27-fluorescein-isothiocyanate (FITC), IgG-Biotin, and 
Streptavidin-PECy7 (Invitrogen). Single cells were sorted on a FACSVantage (BD 
Bioscience) under discrimination of duplets into 96-well plates (Eppendorf) containing 
4µl/well ice-cold lysis buffer with 0.5x phosphate-buffered saline (PBS), 10 mM DTT 
(Invitrogen), 8 U RNAsin® (Promega), and 0.4 U 5 PRIME RNase InhibitorTM (Ep-
pendorf). Plates were sealed with Microseal® ‘F’ Film (BioRad), immediately frozen 
on dry ice, and stored at -80 °C. 
 
2.1.2 Single cell reverse transcriptase (RT) PCR 
cDNA synthesis was performed in a total volume of 14 µl/well containing 
150 ng random hexamer primer (pd(N)6, GE Healthcare), 2 µl of 10 mM dNTP-Mix 
(Invitrogen), 1 µl 0.1 M DTT (Invitrogen), 0.5% v/v Igepal CA-630 (Sigma), 4 U RNA-
sin® (Promega), 6 U 5’ RNase InhibitorTM (Eppendorf), and 50 U Superscript® III re-
verse transcriptase (Invitrogen). RT-PCR reaction was performed according to table 
1. Products were stored at -20 °C. 
METHODS 
 14
Table 1: RT-PCR conditions 
Temperature Time 
42 °C 10 min 
25 °C 10 min 
50 °C 60 min 
94 °C 5 min 
 
2.1.3 IgG gene amplification 
Igγ, Igκ, and Ιgλ chain transcripts were amplified individually in two rounds of 
nested PCR. All reactions were carried out in 96-well plates with 40 µl/well containing 
3.5 µl cDNA or first nested PCR product, respectively.  
 PCR mix: 31.7 µl H2O 
4.2 µl 10x Taq buffer 
0.45 µl dNTPs (each 25 mM) 
7 pmol Ig 5’ Primer 
7 pmol Ig 3’ Primer 
1.2 U HotStar® Taq polymerase 
3.5 µl template DNA 
First round of PCR was performed with a mixture of 5' L-V primers of H or κ/λ 
L chain as forward primers and the according reverse primer (SI: Table 12) Second 
round of PCR was performed with a mixture of 5’ AgeI VH primers and 3’ IgG (inter-
nal) primer for IgH chain, 5’ Pan Vκ and 3’ Cκ 494 primer for Igκ chain, and a mixture 
of 5’ AgeI Vλ primers and 3’ XhoI Cλ for Igλ. Each round of PCR, consisting of 50 
cycles, was performed according to table 2. PCR products were stored at -20 °C. 
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Table 2: IgG gene PCR conditions 
Temperature Time 
94 °C 30 s 
58 °C (γ,κ)/60 °C (λ) 30 s 
72 °C 55 s (1st PCR)/45 s (2nd PCR) 
4 °C hold 
 
2.1.4 Ig gene sequence analysis 
Products of the second PCR were sequenced with the respective reverse 
primers (SI: Table 12) and analyzed for Ig gene usage, CDR3 features, and number 
of V gene mutations using IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/). CDR3 
length was determined by counting the aa following FWR3 up to the conserved tryp-
tophan-glycine motif in JH or the phenylalanine-glycine motif in Jκ and Jλ. The num-
ber of positively (arginine (R), histidine (H), lysine (K)) and negatively (aspartate (D), 
glutamate (E)) charged aa residues were identified for each IgH and IgL CDR3. IgH 
chain D gene reading frames were determined according to Corbett et al. (Corbett, et 
al., 1997). For the analysis of replacement (R) and silent (S) mutations each nucleo-
tide was considered independently unless in rare cases where a combination of nu-
cleotide exchanges within one codon was needed to replace or maintain a specific 
aa. R and S frequencies were calculated according to the number of nucleotides in 
the respective V gene as defined by IgBLAST. Polymorphisms were identified by 
comparison to published germline sequences (http://www.ncbi.nlm.nih.gov/igblast/) or 
own observations. 
 
2.1.5 Cloning of PCR amplificats into expression vectors 
To enable cloning of IgH and Igκ products lacking restriction sites, second 
PCR was repeated as a specific PCR using the respective 5’ AgeI VH and 5’ AgeI Vκ 
gene-specific forward primers and 3’ SalI JH and 3’ BsiWI Jκ reverse primers accord-
ing to gene information received from sequence analysis. The PCR products of the 
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specific PCR for IgH and Igκ and 2nd PCR for Igλ were purified using Qiaquick® 96 
PCR Purification Kit (Qiagen) and QIAvac 96 according to the manufacturer’s instruc-
tions. Samples were eluted with 50 µl nuclease-free water (Eppendorf) resulting in a 
volume of 30-35 µl purified DNA. Digests were undertaken with restriction enzymes 
AgeI, SalI, BsiWI and XhoI (all New England BioLabs) in the according buffer at 
37 °C (except BsiWI at 55 °C) for at least 1h. Following a further purification step, as 
described above, ligation was carried out in a total volume of 10 µl with 1 U T4 DNA-
Ligase (Invitrogen), 7 µl digested and purified PCR product and approximately 25 ng 
of the respective linearized human Igγ1, Igκ, and Igλ expression vector. The vectors 
contained a multiple-cloning site and an ampicillin resistance gene and transcription 
was under the control of the human cytomegalovirus (HCMV) promoter. 
 
2.1.6 Amplification of vector DNA 
For amplification of vector DNA, 10 ng vector DNA was transformed into com-
petent E. coli as stated below (see 2.1.9). A single colony was picked from the Ly-
sogeny broth (LB) agar plate and grown in 2.5 ml LB with 75 µg/ml ampicillin at 37 °C 
in the incubator for 16 h, before transferring the suspension to 250 ml LB with 
75 µg/ml ampicillin for another 16 h in the incubator. Vectors were obtained from the 
bacterial culture by basic lysis and purified using HiSpeed® Plasmid Maxi Kit 
(Qiagen) following the manufacturer’s instructions. Linearization was performed with 
the respective enzymes (SI: Figure 30). Products were separated on a 1% agarose 
gel at 100 V for 30 min, cut from the gel, and purified with a Qiaquick® Gel Extraction 
Kit (Qiagen), according to the protocol. 
 
2.1.7 Production of competent bacteria 
Competent bacteria were produced via calcium chloride treatment. For this, 
bacteria of the E. coli DH10B strain (Clontech) were plated on LB agar plates, and a 
single colony was grown in 4 ml LB medium at 37 °C and 170 rpm for 16-18 h. The 
suspension was transferred into a 1 l Erlenmeyer-flask together with 500 ml LB me-
dium, grown at 37 °C and 170 rpm until an OD of 0.5-0.8 at 600 nm, equally divided 
onto four 400 ml centrifugation tubes, and incubated on ice for 30 min. After centrifu-
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gation at 1600 xg for 10 min at 4 °C, the pellet was resuspended in 80 ml 0.1 M 
CaCl2 and kept on ice for a minimum of 2 h before an additional round of centrifuga-
tion (as above). The supernatant was discarded, the pellet resuspended in 2 ml 0.1 M 
CaCl2 with 15% v/v glycerol, immediately frozen in 100 µl aliquots on dry ice, and 
kept at -80 °C until further use. Competence was confirmed and determined by 
counting the colonies after transformation of different amounts of vector DNA ranging 
between 0.3 ng to 30 ng DNA. Transformation was performed as described below. 
Numbers of colonies were divided by the amount of DNA (µg) and multiplied with the 
ratio of the recovered volume of bacteria (ml) and the volume plated (ml). Typical val-
ues obtained ranged between 5 x 105 to 106 colonies per µg DNA. 
 
2.1.8 Reversion strategy of mutated IgH and IgL chain genes to germ-
line form 
An overlap-PCR strategy was used to revert mutated V(D)J gene segments of 
the IgH and IgL chain to their germline form (Figure 5). V gene segments were ampli-
fied from unmutated templates previously cloned with a gene-specific forward primer 
containing the AgeI restriction site and an individual reverse primer annealing to the 
3’ end of the FWR3 region. CDR3-J segments were reverted with an individual primer 
containing a minimal complementarity of 10 nucleotides with the reverse V segment 
primer. J segment reverse primers contained the respective restriction site. PCR was 
performed at 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 45 s (see also table 2, ac-
cording to conditions for γ,κ and 2nd PCR) for 30 cycles. Equal amounts of PCR 
products were fused in a 20-cycle overlap PCR under the same conditions. Bands of 
the correct full-length size as compared to the respective mutated genes were cut 
and eluted from the gel before restriction and cloning into the respective vectors. 
Gene identity, successful reversion, and correct insertion into the vector were con-
firmed by sequencing the product of the bacterial colony PCR after transformation 
into E. coli DH10B, as described below. 
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Figure 5: PCR strategy for the reversion of somaticly mutated Ig genes to their germ-
line counterparts. Reversion is exemplified on an IgH chain. Asterisks indicate somatic mu-
tations. PCR 1 amplifies a germline VH segment corresponding to the mutated VH segment. 
Primers in PCR 2 revert mutations in CDR3 region and JH segment of the mutated clone. 
Homology of 3' VH specific primer (PCR 1) and 5' reversion primer (PCR 2) are indicated by 
vertical lines. Products from both PCRs are fused in a subsequent overlap PCR using the 
forward primer of PCR 1 and the reverse primer of PCR 2 to generate the complete germline 
VDJ segment. (modified from (Tiller, et al., 2008)) 
 
2.1.9 Transformation of vector DNA into competent E.coli 
Competent bacteria E. coli DH10B were transformed via heat shock at 42 °C 
for 50 sec with 3 µl ligation product. In detail, 7 µl bacteria were mixed with the DNA 
in a 96 well plate (Costar) and incubated on ice 30 min before and 5 min following 
heat shock. 100 µl LB without antibiotics was added to each well and bacteria were 
grown for 30 min at 37 °C in the incubator before plating them on 10 cm LB agar 
plates with 75 µg/ml ampicillin (Sigma). Following an over night incubation at 37 °C in 
the incubator, colonies were screened by PCR with 5’ Ab sense as a forward primer 
and 3’ IgG (internal), 3’ Cκ 494, and 3’ Cλ as reverse primers, respectively. PCR 
products were sequenced to confirm correct insertion into the expression vector ac-
cording to reading frame. Sequences were further blasted using SeqManII 
(DNASTAR) against the original PCR product sequence to exclude mutations intro-
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duced by error-prone Taq polymerase. Plasmid DNA was obtained from 3.5 ml 16-
18 h cultures of bacteria in Terrific Broth (Carl Roth) with 75 µg/ml ampicillin (Sigma) 
by basic lysis using QIAprep® Spin columns (Qiagen). 
 
2.1.10 Production of recombinant antibodies 
Human embryonic kidney (HEK) 293T (ATCC, No. CRL-11268) cells were cul-
tured in 150 mm plates (Falcon, Becton Dickinson) under standard conditions (37 °C 
in a humidified atmosphere containing 5% CO2) in Dulbecco’s Modified Eagle’s Me-
dium (DMEM; GibcoBRL) supplemented with 10% heat-inactivated fetal calf serum 
(FCS) (Invitrogen), 1 mM sodium pyruvate, 100 µg/ml streptomycin, 100 U/ml penicil-
lin G, and 0.25 µg amphotericin B (all GibcoBRL). Heat-inactivation of FCS was per-
formed for 30 min at 56 °C in a water bath before refreezing 50 ml aliquots and stor-
ing them at -20 °C until further use. 
Cells were expanded every two days at a confluency of 80% at a 1:10 dilution. 
For this, cells were washed with 10 ml PBS and incubated in 3 ml trypsin (GibcoBRL) 
for 30-60 s. After trypsin removal and loosening of the cells by repeated tapping of 
the plate, cells were suspended in 20 ml growth medium and 2 ml cell suspension 
were transferred onto a new plate with 20 ml medium.  
Transient transfection with an IgH chain vector and its respective IgL chain 
vector was performed by calcium-phosphate precipitation. In detail, expression vector 
DNA was mixed with 0.7 mM Chloroquine (Sigma) in 1 ml sterile water. 2.5 M CaCl2 
was added drop-wise to a concentration of 250 mM. An equal volume of 2x HEPES-
buffered saline (50 mM HEPES, 10 mM KCl, 12 mM Dextrose, 280 mM NaCl, 
1.5 mM Na2HPO4-7H2O, pH 7.05) was slowly added continuously vortexing the solu-
tion before incubating the whole at room temperature for 10 min to allow the forma-
tion of precipitates. The precipitation-mixture was distributed equally over HEK cells 
with a confluency of 80%. After 8-12 h in the incubator, HEK cells were washed twice 
with 10 ml serum-free DMEM and kept in 25 ml DMEM supplemented with 1% Nutri-
doma-SP (Roche) and antibiotics as stated above for 6 d. Supernatants were har-
vested and cell debris removed by centrifugation at 800 xg for 10 min at 4 °C before 
storage at 4 °C with 0.05 % sodium azide. Production of recombinant antibodies was 
confirmed by enzyme-linked immunosorbent assay (ELISA). 
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2.1.11 Purification of recombinant antibodies 
Recombinant antibodies were purified from the supernatants according to the 
manufacturer’s protocol using Protein G beads (GE Healthcare). Protein G is a strep-
tococcal cell-surface protein with three homologous binding sites that bind IgG with 
high affinity. Briefly, 25 ml supernatant were incubated with 25 µl washed Protein G 
beads on a rotating shaker at 4 °C overnight. After centrifugation at 800 xg for 10 min 
at 4 °C the supernatant was removed and the beads transferred to a chromatography 
spin column (BioRad) equilibrated with PBS. After two rounds of washing with 1 ml 
PBS, bound recombinant antibodies were removed from the beads in three elution 
steps with 200 µl 0.1 M glycine (pH 3.0) each and collected in tubes containing 20 µl 
1 M Tris (pH 8.0) with 0.5 % sodium azide. 
 
2.1.12 IgG concentration ELISA 
High-binding capacity ELISA plates (Costar) were coated with 50 µl/well goat 
anti-human IgG (Fcγ-specific; Jackson) at a concentration of 2 µg/ml in PBS over 
night. Antibody concentrations of HEK cell supernatants were determined using a 
3 µg/ml human serum IgG1 (Sigma) diluted in PBS as a standard. Purified antibodies 
were diluted between 1:50 to 1:150 according to the estimated relative concentration 
by determination of the optical density (OD) at 280 nm. ELISA plates were washed 
three times with 200 µl/well water, blocked with 200 µl/well blocking buffer (2 mM 
EDTA and 0.05 % Tween®-20 in PBS) for 1 h and washed again. Antibodies were 
incubated for 2 h. After a further washing step ELISA plates were incubated with 
50 µl/well horseradish-peroxidase (HRP) conjugated goat anti-human IgG (Jackson) 
at a concentration of 0.8 µg/ml in blocking buffer for 2 h. Unbound antibody was re-
moved by two washing steps including an intermediate rinsing step with 200 µl/well 
blocking buffer. Assays were developed with HRP chromogenic substrate 2,2’-azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS; Pierce) according to the manufac-
turer’s instructions, and OD was measured at 405 nm using SoftMax Pro® software 
(Molecular Devices). All steps were performed at ambient temperature. 
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2.2 Assays determining antibody reactivity 
2.2.1 Polyreactivity ELISA 
Incubation, blocking, and washing was performed as described above for IgG 
concentration ELISA. Antibody supernatants were tested at a concentration of 
1 µg/ml with three consecutive 1:4 dilutions in PBS. High-binding capacity ELISA 
plates (Costar) were coated with 50 µl/well of one of the following antigens: Insulin 
(5 µg/ml), double-stranded (ds) DNA, single-stranded (ss) DNA, or lipopolysaccha-
ride (LPS) (all 10 µg/ml). ssDNA was prepared from salmon sperm dsDNA by boiling 
at 94 °C for 30 min and immediately freezing aliquots at -20 °C. Human recombinant 
insulin solution (Sigma) and LPS from E. coli Serotype 055:B5 (Sigma) were stored 
at 4 °C. For the detection of bound antibodies ABTS (BioRad) was used as a sub-
strate. Controls for polyreactivity were the human recombinant antibodies mGO53 
(negative; (Wardemann, et al., 2003)), eiJB40 (low positive; (Wardemann, et al., 
2003)) and ED38 (high; (Meffre, et al., 2004)) and were included in each plate. Cut-
off OD above which an antibody was counted as reactive was determined for each 
experiment by taking the average OD of eiJB40 and subtracting two times the stan-
dard deviation at a concentration of 1 µg/ml. A minimum of three controls was in-
cluded in each experiment to allow calculation of standard deviation. An antibody was 
counted as polyreactive if it bound at least two structurally different antigens and if 
reactivity was confirmed in at least two independent experiments. 
 
2.2.2 Anti-nuclear antibody (ANA) ELISA 
Self-reactivity of protein G-purified monoclonal recombinant antibodies was 
tested using QUANTA LiteTM ANA ELISA plates coated with HEp-2 cell lysates en-
riched for nuclear antigens (INOVA Diagnostics). Assay procedures were identical to 
polyreactivity ELISA, but starting with an antibody concentration of 10 µg/ml in PBS. 
Negative and low positive controls were used as provided by the manufacturer and 
contained sera from healthy individuals and patients, respectively. Antibodies in ANA 
ELISA were considered self-reactive if reactivity was confirmed in HEp-2 immu-
neofluorescence or immunoblot assay or if they showed strong HEp-2 immuneofluo-
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rescence staining patterns (usually against cytoskeletal antigens which were not 
abundant in the ANA ELISA). 
 
2.2.3 Anti-Ro/SSA and Anti-La/SSB ELISA 
Anti-Ro/SSA and anti-La/SSB reactive protein G-purified monoclonal recombi-
nant antibodies in their mutated and reverted form were tested on ELISA plates con-
taining purified recombinant Ro/SSA or La/SSB protein (ORGENTEC Diagnostika). 
Assay procedures were identical to polyreactivity ELISA, but starting with an antibody 
concentration of 1 µg/ml in PBS for Ro/SSA and 10 µg/ml in PBS for La/SSB due to 
less intense reactivity of anti-La/SSB antibodies in ANA ELISA. 
 
2.2.4 HEp-2 immunofluorescence assay 
HEp-2 cell coated slides (BIOS GmbH) were incubated in a moist chamber 
with 20 µl purified antibodies at a concentration of 50-150 µg/ml for 30 min. Slides 
were washed three times in PBS for 5 min and subsequently incubated with 20 µl 
FITC-labeled goat anti-human Ig according to the manufacturer’s instructions. After 
an additional washing step, slides were coated with Fluoromount-G (SouthernBio-
tech) and sealed with a glass cover slip. Edges between slide and cover slip were 
additionally sealed with nail polish. Control stainings, including PBS, ANA-negative, 
and positive control, were applied as suggested by the manufacturer and incorpo-
rated in all assays. Samples were examined on a Zeiss Axioplan 2 fluorescence mi-
croscope (Carl Zeiss MicroImaging). Stainings were evaluated in comparison to con-
trols at equal exposure times. 
 
2.2.5 Immunoblot assay 
Immunoblot assay (INNO-LIA ANA Update; Innogenetics) was performed to 
determine reactivity of purified recombinant antibodies with specific disease-related 
antigens according to the manufacturer’s instructions. In brief, antibodies were tested 
at a concentration of 2 µg/ml or human serum at a dilution of 1:100 in the provided 
solution for 1 h. After three times washing for 3 min, the blot stripes were incubated in 
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2 ml of the conjugate-solution, containing an alkaline phosphatase-labeled goat anti-
human IgG antibody, for 1 h. After an additional washing step, bound antibody was 
made visible by adding 2 ml of the chromogen BCIP/NBT. After 30 min, further stain-
ing was prevented by transferring the stripes into sulfuric acid to inhibit the activity of 
the alkaline phosphatase. A cut-off control was included in each assay. 
 
2.3 Statistics 
2.3.1 Statistical analysis 
P-values for Ig gene repertoire analysis, analysis of positive charges in IgH 
CDR3, and antibody reactivity were calculated by 2 x 2 or 2 x 5 Fisher’s Exact test or 
Chi Square Test. P-values for IgH CDR3 length were calculated by non-paired two-
tailed Student’s t-test. P-values for V gene FWR1-FWR3 mutations were calculated 
by non-parametric Mann-Whitney U test. P-values for ratios of VH to VL gene SHM 
were calculated by 1 way ANOVA analysis. 
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3 RESULTS 
 
3.1 Clinical features of four analyzed SLE patients 
The blood samples were obtained from four newly diagnosed, untreated, pe-
diatric SLE patients (169, 174, 175, and 176) with active disease. The patients' clini-
cal features were diverse as were the autoantibody specificities in the patients’ sera 
reflecting the heterogeneity of the disease. All of the patients were anti-nuclear anti-
body (ANA) positive with different serum specificities including reactivities against 
dsDNA, Smith-antigen, Cardiolipin, ribonuclearproteins (RNP), and other ENAs. Two 
patients showed lupus nephritis and three patients exhibited a decrease in comple-
ment components (Table 3). 
 
Table 3: Patients’ characteristics 
Patient SLE169 SLE174 SLE175 SLE176 
Gender F F F F 
Age (yr) 12 17 11 13 
Treatment none none none none 
Clinical features arthritis malar rash, arthritis pain, hypothyroidism rash 
Lupus nephritis IV / / V 
ANA + + + + 
C3 complemtent (mg/dl) 28 78 176 65 
C4 complemtent (mg/dl) <6 15 40 4 
Serology D, CL ENA/RNP, Sm ENA/RNP, Sm D, ENA/RNP, Sm 
D, anti-dsDNA antibodies; CL, anti-cardiolipin antibodies; Sm, anti-Smith antibodies; 
ENA/RNP, anti-extractable nuclear antigen/anti-ribonucleoprotein antibodies; normal values 
for complement: C3 90-180 mg/dl, C4 10-40 mg/dl (Herold, 2003). 
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3.2 B cell FACS staining patterns of SLE patients 
To characterize the IgG antibodies expressed by circulating memory B cells in 
SLE, IgG+ memory B cells (CD19+CD27+IgG+CD38-) were isolated from peripheral 
blood of the patients by FACS (Figure 6). A previously reported increased population 
of CD38+CD27++ plasmablasts with low levels of IgG was only found in patient 
SLE169 (Figure 6; (Arce, et al., 2001; Odendahl, et al., 2000; Vallerskog, et al., 
2007)). The IgH and IgL chains were cloned from the IgG+ memory B cells as previ-
ously described (chapter 2.1 and (Tiller, et al., 2008)). None of our reactivity assays 
showed a significant difference between CD38- memory B cells and CD38+ plasmab-
lasts in SLE169, and therefore these were considered together (Figure 6 and SI: Ta-
ble 5). 
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Figure 6: Surface staining and gates for FACS purification of single IgG+ memory B 
cells from healthy controls and SLE patients. Pre-enriched B cells were stained for sur-
face expression of CD19, CD38, CD27 and IgG. CD19+CD38- cells and CD19+CD38+ cells 
(left) were further analyzed for CD19 and IgG expression (right). Boxed CD38-
CD19+IgG+CD27+ memory B cells from SLE169, SLE174, SLE175, and SLE176 and 
CD38+CD19+IgG+CD27+ plasmablasts from SLE169 were single cell FACS sorted (right) be-
fore amplification of Igγ H and corresponding IgL chains (SI: Tales 5-9). 
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3.3 Molecular features of SLE IgG+ memory B cells 
3.3.1 IgH chain gene usage and CDR3 characteristics 
None of the analyzed sequences were clonally related (SI: Table 5-9) and the 
majority of the functional genes were used in SLE IgG+ memory B cells (SI: Table 5-
8; (Lefranc, et al., 2005)). Previous reports showed abnormalities in the distribution of 
IgVH chain gene segments in different developmental B cell stages of SLE patients 
as compared to HC (Dorner, et al., 1999; Fraser, et al., 2003; Pugh-Bernard, et al., 
2001). The comparison of the VH gene family usage of IgG+ memory B cells of SLE 
patients and HC showed no significant difference. In both groups VH3 was predomi-
nantly expressed, followed by VH4, VH1, VH5, and VH7 family members (Figure 7A 
top and SI: Figure 21A). IgH chain diversity (D) and joining (J) gene segments were 
also comparable in their distribution among SLE patients and HC, with the majority of 
the B cells expressing DH3 and nearly half expressing JH4 (Figure 7A middle and 
bottom and SI: Figure 21A). 
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Figure 7: IgH chain gene features from IgG memory B cell antibodies of SLE patients 
and healthy controls. Ig gene repertoire and Ig gene features of IgG memory B cell antibod-
ies cloned from three published (Tiller, et al., 2007) and one unpublished healthy control (HC-
JH) and four patients with SLE (SLE169, SLE174, SLE175, SLE176). P-values compare data 
from the patients to the healthy controls. Pie charts depict VH, DH and JH gene usage (A) 
and the frequency of IgH CDR3s with 0, 1, 2 or ≥ 3 positive (top) and negative (middle) 
charges (B). The absolute number of sequences analyzed is indicated in the center of each 
pie chart. Bar graphs show the frequency of antibodies with CDR3 regions of ≤ 9 aa (white 
bars), 10-14 aa (light gray bars), 15-19 aa (dark gray bars) or ≥ 20 aa (black bars). The aver-
age CDR3 length in aa is indicated above the bar graphs. 
CDR3 features such as charged aa and length have been associated with 
autoreactivity (Crouzier, et al., 1995; Radic, et al., 1993). To determine if abnormali-
ties in the CDR3s of IgG+ memory B cells are a feature of SLE, the number of posi-
tively (arginine, lysine, histidine) and negatively (aspartic acid, glutamic acid) charged 
aa were quantified as a first step. CDR3s lacking positively charged aa were in-
creased in SLE as compared to HC, but this did not reach statistical significance 
(40.0% in SLE vs. 32.3% in HC, P=0.133; Figure 7B top). The frequency and distribu-
tion of negatively charged aa was nearly identical in SLE and HC (P=0.563; Figure 
7B middle). The analysis of the CDR3 length as determined by the number of aa 
showed no significant difference between SLE and HC (14.0 vs 13.7, P=0.497; Fig-
ure 7B bottom). This held true if either the average CDR3 lengths were compared or 
the distribution of CDR3 length ranges among different clusters. About half of the 
CDR3 lengths belonged to the cluster containing 10-14 aa (50.6% in SLE and 47.5% 
in HC), and extremely long CDR3s with 20 aa and more were found in less than 8% 
of the antibodies in both SLE and HC (7.8% in SLE and 7.1% in HC; Figure 7B bot-
tom). 
 
3.3.2 IgL chain gene usage 
Differences in the usage of IgL chain genes have been reported to be a fea-
ture of SLE (de Wildt, et al., 2000; Dorner, et al., 1999). Therefore, the usage of Igκ 
and Igλ L chain gene segments between IgG+ memory B cells of SLE patients and 
HC was compared. Igκ L chain usage in SLE differed significantly from normal 
through an increase in Vκ2 family usage (13.8% in SLE vs. 4.7% in HC, P=0.027; 
Figure 8A and SI: Figure 22A). The expression of individual Vκ gene segments was 
further analyzed and revealed an underrepresentation of Vκ3-20, which was consis-
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tent in all SLE patients (on average 10.3% in SLE and 26.2% in HC; SI: Figure 25 
and 26). The Jκ usage was comparable between SLE and HC with Jκ1 being primar-
ily expressed followed by Jκ2 and Jκ4. Significant differences in Igλ L chain usage 
could not be observed. Vλ1 and Vλ2 were primarily expressed in both groups (36.5% 
and 40.5% in SLE vs. 41.0% and 38.6% in HC, respectively). Vλ3 was enhanced in 
SLE (16.7% in SLE vs. 8.4% in HC) and Vλ7 was reduced (0.8% in SLE vs. 8.4% in 
HC), but this did not reach statistical relevance (P=0.072; Figure 8B top). Further did 
the inverse distribution of Jλ2 and Jλ3 between SLE and HC not lead to a significant 
difference (35.7% and 46.8% in SLE and 44.6% and 37.3% in HC, respectively, 
P=0.430; Figure 8B bottom). However, SLE patients exhibited a consistent overex-
pression of Igλ L chain genes (46% in SLE vs. 32% in HC, P=0.0004; Figure 8 and 
SI: Table 5-8; (Tiller, et al., 2007)). 
 
 
Figure 8: IgL chain gene features from IgG memory B cell antibodies of SLE patients 
and healthy controls. Ig gene repertoire and Ig gene features of IgG memory B cell antibod-
ies cloned from three published (Tiller, et al., 2007) and one unpublished healthy control (HC-
JH) and four patients with SLE (SLE169, SLE174, SLE175, SLE176). P-values compare data 
from the patients to the healthy controls. Pie charts depict Vκ/Jκ (A) and Vλ/Jλ gene family 
usage (B). The absolute number of sequences analyzed is indicated in the center of each pie 
chart. The frequency of Igκ and Igλ light chain positive antibodies is indicated below. 
 
3.3.3 Individual differences of SLE patients 
Analyzing the SLE patients individually revealed a number of unusual fea-
tures. SLE174 showed a significant difference in the DH repertoire. DH1 and DH3 
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were reduced (2.2% and 32.6% in SLE vs. 8.9% and 41.9% in HC, respectively) 
while DH4 and DH6 were increased (15.2% and 26.1% in SLE vs. 5.6% and 14.0% in 
HC, respectively) (P=0.047; SI: Figure 21A middle). Even more striking were the indi-
vidual differences in SLE169. First of all, the CDR3 length showed a significant in-
crease (average 15.1 aa vs. 13.9 aa in HC, P=0.012; SI: Figure 21B bottom). Analyz-
ing the single VH gene segments showed an overrepresentation of VH 4-4 (15.6% 
vs. 1.6% in HC and 2.2% in the other SLE patients; SI: Figure 23 and 24 and Tables 
5-9 (Tiller, et al., 2007)). The IgV L chain repertoire exhibited a lower frequency of the 
Vλ2 gene family (25.0% vs. 38.6% in HC), whereas the Vλ3 family gene usage was 
increased in SLE169 (25.0% vs. 8.4% in HC, P=0.005; SI: Figure 22B top). IgG+ 
memory B cells from this patient were further unusual in that >25% of the B cells ex-
pressed both a functional Igκ and Igλ L chain as compared to 0% in healthy controls 
and 0-2% in the other SLE patients (SI: Table 5 and 10 (Tiller, et al., 2007)).  
To elucidate possible mechanisms behind allelic inclusion such as tolerance 
induction in Igκ+Igλ+ double expressing B cells in SLE169, self-reactivity of the anti-
bodies with either Igκ or Igλ L chain were compared. Igλ L chain antibodies exhibited 
autoreactivity only in concordance with the respective Igκ L chain antibody, whereas 
one third of the antibodies were self-reactive only with the Igκ L chain (Table 4). 
 
Table 4: Self-reactivity of antibodies with two functional IgL chains from pa-
tient SLE169 
κ+λ+ λ 
SLE169 self-reactive non self-reactive
self-reactive 13.3% 33.3% 
 
κ 
  non self-reactive 0% 53.3% 
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3.3.4 Secondary rearrangement and IgV to IgJ gene segment joining 
in SLE 
Secondary rearrangement on the IgL chain loci as a mechanism to alter re-
ceptor specificities has been evident in transgenic mice expressing an anti-dsDNA-
reactive H chain, through an increased usage of the most downstream Jκ5 gene 
segment (Radic, et al., 1993). In human autoimmune diseases, an increase as well 
as a decrease of secondary L chain rearrangement has been reported (Bensimon, et 
al., 1994; Dorner, et al., 1998; Samuels, et al., 2005; Yurasov, et al., 2006). Due to 
their spatial proximity on the gene locus, VL chain gene segments are most likely 
joined to upstream JL chain gene segments in a primary rearrangement. During fur-
ther rearrangement they are deleted from the locus so that an increased joining of 
upstream V gene segments to downstream J gene segments argues for enhanced 
secondary rearrangement. A distinct feature of the Igκ locus, however, is that a num-
ber of V gene segments are present in the reverse orientation to that of the J gene 
segments. They rearrange by inversion, thus retaining the V gene segments further 
downstream, which can then be used during a further rearrangement (Schroeder, 
2006). A primary rearrangement can therefore only be identified through the usage of 
Jκ1. 
To check for major changes in the joining of Vκ to Jκ gene segments in SLE 
IgG+ memory B cells, the events within a single cell were visualized in a graph with 
the V gene segments on the ordinate and the J gene segments on the abscissa (Fig-
ure 9). The increased usage of Jκ1 or Jκ2 would argue for an increased presence of 
primary rearrangements. A cluster of joining events in the upper right corner would 
argue for an increase in secondary rearrangement. A major difference in the distribu-
tion of Vκ to Jκ joining events between SLE and HC was not observed (Figure 9). 
The majority of the events clustered around the individual genes mostly used, e.g. 
Vκ3-20 and Vκ1-5 (compare also SI: Figures 25 and 26), and the frequency of Jκ3, 
4, and 5 joining events to Vκ3-15 and above was comparable (27% for HC and 23% 
for SLE). 
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Figure 9: Vκ to Jκ joining in SLE patients and healthy controls. Dots indicate joining of V 
to J gene segments of single Igκ L chains. The most proximal V and J gene segments are 
closest to the origin of each graph. 
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Signs of enhanced rearrangement on the Igλ L chain locus have been re-
ported in SLE (Dorner, et al., 1999). To determine if differences in secondary rear-
rangement on the Igλ locus play a role in SLE IgG+ memory B cells, the joining of Vλ 
to Jλ of SLE patients and HC, as described above for the Vκ to Jκ joining, was ana-
lyzed. Since Igλ does not rearrange by inversion, a clustering of joining events in the 
lower left or the upper right corner could be interpreted as a decrease or an increase 
in secondary rearrangement, respectively. Again, the joining events were comparable 
between HC and SLE, and there was no evidence for an alteration in the Vλ to Jλ 
joining in SLE (Figure 10). The frequency of Jλ3 joining to Vλ1-36 and above was 
similar (24% for HC and 20 % for SLE), and the increased presence of Jλ3 in SLE 
was also associated with an increased joing to downstream Vλ gene segments. 
 
 
Figure 10: Vλ to Jλ joining in SLE patients and healthy controls. Dots indicate joining of 
V to J gene segments of single Igλ L chains. Proximal V and J gene segments are closest to 
the origin of each graph. 
 
Even though the primary rearrangement on the IgH chain locus deletes all the 
unrearranged D segments and a secondary rearrangement would contradict the 12-
23 spacer rule, a number of studies has reported a VH replacement on the H chain 
locus (Chen, et al., 1995; Deane and Norton, 1990; Kleinfield, et al., 1986; Reth, et 
al., 1986; Wilson, et al., 2000; Zhang, et al., 2003). The remaining nucleotides of the 
VH segment of the first rearrangement are not unambiguously distinguishable from N 
addition, and to determine if unusual rearrangements of the IgH chains were enriched 
in the SLE IgG+ memory B cell pool, the joining of VH to JH gene segments was ana-
lyzed. No general difference was observed between SLE patient and HC (Figure 11). 
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The majority of the VH to JH joining events was comparable between SLE patients 
and HC and differences resulted from unsignificant general changes in the gene 
segment usage (for example a reduced expression of JH1 in SLE, 0.8% vs. 3.1% in 
HC; Figure 7A bottom and 11). 
 
 
Figure 11: VH to JH joining in SLE patients and healthy controls. Dots indicate joining of 
V to J gene segments of single IgH chains. Proximal V and J gene segments are closest to 
the origin of each graph (Lefranc, et al., 2005). 
 
3.3.5 IgG isotype subclass distribution 
The IgG isotype subclasses have been attributed to different effector functions such 
as Fcγ receptor binding or activation of complement (Bindon, et al., 1988; Nimmer-
jahn and Ravetch, 2008). The subclasses expressed by the IgG+ memory B cells 
could be determined by analyzing the sequences of the 2nd PCR products (chapter 
2.1.3 and (Tiller, et al., 2008)). Three of the four patients (SLE169, SLE175, and 
SLE176) showed a significant alteration in the distribution of their IgG subclasses 
(P ≤ 0.005; Figure 12). IgG1 was increased in SLE175 (77.0% vs 66.7% in HC). 
SLE169, SLE175, and SLE176 all displayed a bias towards IgG3 (23.1%, 18.0%, and 
24.6%, respectively vs. 6.3% in HC) and reduced expression of IgG2 (7.7%, 4.9%, 
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and 15.8%, respectively vs. 23.4% in HC). Only SLE174 exhibited the normal distri-
bution dominated by IgG1 and IgG2 (P=0.945; Figure 12). 
 
 
Figure 12: IgG isotype subclass distribution in IgG+ memory B cells of SLE patients 
and healthy controls. Bar graphs show IgG1 (white bars), IgG2 (black bars), IgG3 (dark 
gray bars) and IgG4 (light gray bars bars) subclass frequencies. P-values compare individual 
patients to healthy controls. Standard deviations are indicated for healthy controls. 
 
3.3.6 Mutational frequency of IgVH and VL gene segments 
The mutational frequency has been reported to be increased in SLE IgG+ 
memory B cells (Dorner, et al., 1999; Dorner and Lipsky, 2001). Therefore the num-
ber of nucleotide exchanges in the IgH and IgL V gene segments (VH, Vκ, and Vλ) 
cloned from the SLE patients was determined. A significant decrease was found in all 
V gene segments in comparison to HC. The average number of mutations in VH 
showed a reduction from 17.6 in HC to 11.2 in SLE (P<0.0001), in Vκ the numbers 
dropped from 9.6 in HC to 5.6 in SLE (P<0.0001), and in Vλ from 8.1 in HC to 5.4 in 
SLE (P<0.0001; Figure 13 and SI: Figure 29; (Tiller, et al., 2007)). 
RESULTS 
 36
 
Figure 13: Number of somatic hypermutations in SLE patients and healthy controls. 
Dots represent individual VH, Vκ, and Vλ genes of antibodies from IgG+ memory B cells of 
four healthy donors (filled circles) and four SLE patients (open circles). Horizontal lines rep-
resent the average number of mutations and gray bars represent the standard deviation to 
show variability of mean values among individuals. P values are depicted comparing SLE 
patients and healthy controls. 
 
The ratios of replacement (R) to silent (S) somatic hypermutations (SHM) in 
the FWRs and the CDRs of the IgV gene segments are an indicator for antigen-
driven selection processes. To estimate if the observed reduction in the mutational 
frequency of the SLE IgG+ memory B cells was linked to defects in selection, the R/S 
ratios of the SLE IgH and IgL V gene segments were compared to those of the HC. 
The lower frequency of SHM was not associated with considerable alterations in the 
R/S ratio in the SLE IgG+ memory B cells (Figure 14). The absolute ratios between 
HC and SLE were comparable (2.1 vs. 2.0 for VH, 1.9 vs. 1.9 for Vκ, and 2.2 vs. 2.1 
for Vλ, respectively), and R/S ratios were generally higher in the CDRs than in the 
FWRs (2.3 to 6.7 vs. 0.9 to 1.8, respectively; Figure 14). 
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Figure 14: R/S ratios in SLE patients and healthy controls. Bar graphs indicate the fre-
quency of R (black bars) and S (white bars) nucleotide exchanges per base pair in FWRs 
and CDRs in VH, Vκ, and Vλ gene segments. Standard deviations are indicated. The R/S 
ratio for each region is shown below the graphs. 
 
The mutational frequency moreover did not correlate with the patients’ age. 
For example, the youngest patients, SLE175, showed the highest average number of 
V gene SHM of all and the average number of VH gene SHM was lower in SLE174 
than in the age-matched HC PN (10.5 vs 17.0; SI: Figure 29). The average number of 
mutations was generally higher in VH than in VL genes in HC and SLE (Figure 13). 
Strikingly, in SLE169 the ratio of VH to VL gene SHM was significantly increased (4.6 
as compared to 2.4-2.7 in the other SLE patients, P=0.005, and 2.3-3.0 in HC, 
P=0.001; Figure 15 and SI: Table 5-9; (Tiller, et al., 2007)). The association of a mu-
tated IgH with an unmutated IgL chain was further more frequently detected than in 
the other SLE patients or HC. 
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Figure 15: Ratios of VH to VL mutations. Dots show ratios of VH to VL mutations of single 
antibodies cloned from single IgG+ memory B cells from healthy donors JH, HW, PN, and VB 
and SLE patients 169, 174, 175, and 176. Absolute numbers of V gene segment FWR1-
FWR3 nucleotide exchanges as compared to germline were used for the calculation. In 
cases were mutated IgH chains were associated with unmutated IgL chains (Tables 5.1-5), 
VL mutation values were artificially set from 0 to 1. P-values indicate variance and were cal-
culated using 1 way ANOVA analysis. Horizontal lines represent mean values. 
 
In summary, antibodies cloned from IgG+ memory B cells of SLE patients 
showed a decrease in SHM, an increase in Igλ chain usage, alteration in the IgVκ2 
gene family and IgVκ3-20 gene segment usage, whereas abnormalities in Ig gene 
features such as IgDH usage, IgH CDR3 length, IgVλ usage, and IgG isotype sub-
class distribution were variable among patients. 
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3.4 Polyreactive and self-reactive IgG memory B cells antibod-
ies in SLE 
3.4.1 Polyreactivity in IgG memory B cell antibodies 
In healthy humans, substantial numbers of IgG+ memory B cells express self-
reactive and polyreactive receptors (Koelsch, et al., 2007; Tiller, et al., 2007). To de-
termine the frequency of polyreactive IgG+ memory B cells in patients with SLE, the 
200 recombinant antibodies were tested for reactivity against ssDNA, dsDNA, insulin, 
and LPS. Antibodies reactive to at least two of these structurally diverse self and non-
self antigens were considered polyreactive. Polyreactive IgG+ memory B cells were 
found in all the SLE patients but the frequency of such cells was not significantly dif-
ferent from HC (26% SLE169, 18% SLE174, 15% SLE175, and 21% SLE176 as 
compared to 23% for four HC; Figure 16; (Tiller, et al., 2007)). Further, most of the 
antibodies revealed only low levels of polyreactivity. A small number of highly polyre-
active antibodies was found in SLE169, but not in the other patients. Thus, the gen-
eral frequency of polyreactive IgG+ memory B cells in SLE was not significantly dif-
ferent from HC (23% in healthy vs. 22% in SLE, P=0.711; Figure 16; (Tiller, et al., 
2007)). 
Since CDR3 length has been associated with polyreactivity (Crouzier, et al., 
1995; Ichiyoshi and Casali, 1994; Klonowski, et al., 1999), it was assessed compar-
ing polyreactive and non-polyreactive antibodies of SLE patients and HC. While the 
CDR3 lenth was significantly increased in polyreactive antibodies cloned from SLE 
patients, this was not the case for the HC (15.2 vs. 13.8 in SLE, respectively, 
P=0.037 and 13.7 vs 13.8 in HC, respectively, P=0.854, SI Table 5-9 (Tiller, et al., 
2007)). 
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Figure 16: Polyreactivity of IgG memory B cell antibodies from SLE patients. IgG mem-
ory B cell antibodies from healthy donor JH and patients with SLE were tested for polyreac-
tivity by ELISA with dsDNA, ssDNA, LPS, and insulin. (A) Dotted lines represent the high 
positive control antibody ED38 (Meffre, et al., 2004). Horizontal lines show cut-off OD405 for 
positive reactivity. Green and red lines show the negative control antibody mGO53 and low 
positive control antibody eiJB40, respectively (Wardemann, et al., 2003). (B) Pie charts 
summarize the frequency of polyreactive (black) and non-polyreactive (white) IgG+ memory 
B cell clones from three published (Tiller, et al., 2007) and one additional healthy control (HC-
JH) and of the individual SLE patients. The number of tested antibodies is indicated in the 
center of each pie chart. P-values are in comparison to the four healthy controls (Tiller, et al., 
2007). 
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3.4.2 Self-reactivity in IgG memory B cell antibodies 
HEp-2 cell ELISA, enriched for nuclear antigens, and indirect immunofluores-
cence assay (IFA) are clinical tests to detect ANAs, which are a hallmark feature of 
SLE (Egner, 2000). To determine the frequency of ANAs produced by IgG+ memory B 
cells in SLE, all 200 purified recombinant antibodies were tested by HEp-2 cell ELISA 
and IFA. Surprisingly, no general increase in self-reactivity as compared to HC was 
found (on average 33% in HC vs. 30% in SLE; Figure 17; (Tiller, et al., 2007)). Addi-
tionally, the IFA staining patterns of the recombinant SLE antibodies were indistin-
guishable from HC showing diverse nuclear and cytoplasmic staining patterns (Figure 
17B and C; (Tiller, et al., 2007)). Nevertheless, two antibodies (107, 128) cloned from 
SLE175 exhibited a high level of self-reactivity in the HEp-2 cell ELISA, that had not 
been observed in any of the other SLE patients or HC. These two antibodies further 
differed from other self-reactive antibodies in the ELISA, such as gp103κ from 
SLE169, in that they did not show any sign of reactivity in the polyreactivity ELISA 
(Figure 17A and SI: Table 5 and 7). 
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Figure 17: Self-reactive antibodies in the SLE IgG+ memory B cell pool. (A) IgG memory 
B cell antibodies from healthy control JH and patients with SLE were tested for self-reactivity 
by HEp-2 cell ELISA. Horizontal line shows ELISA cut-off OD405 for positive reactivity and 
red line shows low positive control serum. For each individual the number of HEp-2 cell self-
reactive antibodies out of all antibodies tested is shown below the graphs. (B) IFA shows 
typical HEp-2 cell staining patterns of antibodies cloned from IgG+ memory B cells of healthy 
donor JH and patients with SLE. Staining pattern of a non-self-reactive antibody (negative) by 
IFA and HEp-2 ELISA is shown for comparison. (C) Pie charts summarize the frequency of 
self-reactive IgG memory B cell antibodies from healthy controls and SLE patients with nu-
clear (black), nuclear plus cytoplasmic (dark gray), and cytoplasmic (light gray) HEp-2 cell 
IFA staining patterns, and the frequency of non-reactive antibodies (white). The number of 
tested antibodies is indicated in each pie chart center. P-values are in comparison to IgG 
memory B cell antibodies from four healthy controls (Tiller, et al., 2007). 
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3.4.3 SLE IgG+ memory B cells producing anti-Ro and anti-La specific 
antibodies 
In order to determine whether any of the recombinant SLE antibodies showed 
specificity for SLE-associated autoantigens and to identify the cognate antigens of 
the two antibodies cloned from SLE175 (107, 128) that where strongly self-reactive in 
the HEp-2 cell ELISA, they were tested on a line immunoblot assay (LIA). LIA is a 
clinical assay, which enables to simultaneously test for reactivity against 13 purified 
SLE antigens on a membrane. For comparison an additional number of 84 recombi-
nant antibodies cloned from HC was tested. From the 200 SLE antibodies tested, six 
showed reactivity against the ribonuclear proteins Ro/SSA and La/SSB in this assay, 
including antibodies 107 and 128, and none of the antibodies from the HC were reac-
tive. All of the reactive antibodies came from patient SLE175, which had serum titers 
of the same specificities in this assay (Figure 18A). None of the antibodies were 
clonally related (SI: Table 7). Two antibodies (107, 128) were reactive against Ro52 
and four were reactive with La (29, 162, 264, 276). One anti-La antibody further ex-
hibited low cross-reactivity with Ro60 (29). Ro and La reactivity was further confirmed 
in an ELISA and with surface plasmon resonance with purified Ro and La, respec-
tively (Figure 19 and data not shown). The anti-Ro and anti-La autoantibodies were 
encoded by uniquely rearranged IgH and Igκ L chain genes (SI: Table 7). They were 
highly mutated and the mutation frequency was significantly increased in comparison 
to the other IgG memory B cell antibodies cloned from patient SLE175 (P=0.003; SI: 
Figure 29 and Table 7). Although the patients’ sera displayed reactivity against 
dsDNA, RNP, or Sm, specific antibodies to these antigens among the 200 tested 
were not identified. In summary, a high frequency of IgG+ memory B cells producing 
SLE antibodies (6/39, 15%) was found in one of the four patients, and these antibod-
ies reflected the specificity of serum autoantibodies measured in this patient (Figure 
18 and Table 3). 
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Figure 18: Ro52/SSA-reactive and La/SSB-reactive SLE IgG memory B cell antibodies. 
(A) Line immunoblot assays with 13 SLE-associated autoantigens (SmB, SmD, RNP-70k, 
RNP-A, RNP-C, Ro52/SSA, Ro60/SSA, La/SSB, Cenp-B, Topo-1/Scl-70, Jo-1/HRS, Ribo-
somal P, Histones) identified four La/SSB-reactive (29, 162, 264, 276) and two Ro52/SSA-
reactive (107, 128) antibodies among 200 tested IgG memory B cell antibodies from SLE 
patients and 84 tested IgG memory B cell antibodies from healthy controls. Anti-Ro52/SSB 
and anti-La/SSB antibodies were all from SLE175. LIA result obtained with serum from the 
same patient is shown for comparison. HEp-2 cell IFA staining patterns of the same antibod-
ies are shown. (B) Germline versions of the two anti-Ro52/SSA and four anti-La/SSB reactive 
IgG memory B cell antibodies from SLE175 were tested by LIA and IFA as in (A). 
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3.4.4 Reversion of mutations of anti-Ro and anti-La specific autoanti-
bodies 
Numerous studies report autoantibody specificities to be generated by SHM 
through the introduction of new aa residues (Radic, et al., 1993; Wellmann, et al., 
2005). To determine if anti-Ro52 and La-reactivity was due to SHM, a PCR-based 
strategy was applied to revert the mutated IgH and IgL chain genes of the six anti-
Ro52 and anti-La antibodies to their germ-line sequence (Figure 5). Thereafter, the 
reverted antibodies were compared for their reactivity in our HEp-2 cell ELISA, IFA, 
and LIA to their mutated counterparts. In the absence of SHM five of six antibodies 
lost reactivity in HEp-2 cell ELISA, IFA, LIA, and ELISA with purified Ro and La, re-
spectively (Figure 18B and 19). Only one of the germ-line antibodies, 128rev, re-
tained a low level of HEp-2 cell reactivity in the ELISA and IFA. The same antibody 
was also reactive with Ro52 in the LIA and ELISA with purified Ro. To determine if the 
anti-Ro and anti-La antibodies arose from polyreactive precursors, the reverted anti-
bodies were tested in the polyreactivity-ELISA. Only 128 showed unspecific polyreac-
tivity in the germ-line form (SI: Table 11). 
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Figure 19: Ro52/SSA-reactive and La/SSB-reactive SLE IgG memory B cell antibodies. 
Results of HEp-2 ELISA (A) and ELISA with purified recombinant Ro and La protein (B) and 
(C) of recombinant mutated (filled symbols) anti-La/SSB (29, 162, 264, 276; left graph) and 
anti-Ro52/SSA (107, 128; right graph) antibodies and their germline counterparts (open sym-
bols). Red lines in the HEp-2 ELISA graphs represent low positive control serum (A), dotted 
lines represent positive control antibody ED38 (Meffre, et al., 2004) and horizontal lines show 
cut-off OD405 for positive reactivity (A), (B). Bar graphs show OD405 of mutated (black) and 
reverted (gray) anti-La/SSB and anti-Ro/SSA antibodies at 10 or 1 µg/ml, respectively (C). 
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To confirm the role of SHM in the generation of Ro52 and La reactive antibod-
ies, an additional number of 21 randomly selected mutated SLE IgG memory B cell 
antibodies was reverted to their germ-line form and tested for polyreactivity and self-
reactivity by ELISA and IFA. The majority of the mutated polyreactive and self-
reactive antibodies lacked reactivity in their germ-line form (8/11, 72.7% and 12/18, 
66.7%, respectively; Figure 20A and B, and SI: Table 11). Only a few antibodies sho-
wed self-reactivity and polyreactivity independent of SHM (5/27, 18.5% and 4/27, 
14.8%, respectively), including 128rev with specificity for Ro52 in the mutated form. 
The germ-line form of all other Ro52 and La reactive antibodies lacked polyreactivity 
(Figure 20 and SI: Table 11). 
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Figure 20: Somatic hypermutation contributes to poly-reactivity and self-reactivity in 
IgG memory B cell antibodies in SLE. (A) IgH and IgL chains from IgG memory B cell anti-
bodies of SLE patients were reverted into their germline counterparts by PCR. Recombinant 
mutated (left) IgG memory B cell antibodies and their germline counterparts (right) were 
tested for polyreactivity (A) and self-reactivity by HEp-2 cell ELISA (B) and IFA (C). (A) 
Polyreactive mutated (top left) antibodies and mutated non-polyreactive (bottom left) antibod-
ies were tested for polyreactivity by ELISA and compared to their germline counterparts 
(right). Representative polyreactivity graphs with dsDNA as antigen are shown. Dotted lines 
represent the high positive control antibody ED38 (Meffre, et al., 2004), red lines represent 
the low positive control antibody eiJB40 and green lines represent the negative control anti-
body mGO53 (Wardemann, et al., 2003). Horizontal lines show cut-off OD405 for positive re-
activity. (B) HEp-2 cell self-reactive mutated (top left) antibodies and mutated non-self-
reactive (bottom left) antibodies were tested for HEp-2 cell self-reactivity by ELISA and com-
pared to their germline counterparts (right). Red lines represent low ANA serum controls and 
horizontal lines show cut-off OD405 for positive reactivity. (C) Typical HEp-2 cell IFA staining 
patterns of mutated IgG memory B cell antibodies (left) and their germline counterparts 
(right). 
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4 DISCUSSION 
 
4.1 IgG+ memory B cells in patients with SLE 
Abnormalities in the IgH and IgL chain repertoire of B cells in the autoimmune 
disease systemic lupus erythematosus have been reported (Bensimon, et al., 1994; 
Dorner, et al., 1999; Dorner and Lipsky, 2001; Manheimer-Lory, et al., 1997; Pugh-
Bernard, et al., 2001; Suzuki, et al., 1996; Yurasov, et al., 2006; Yurasov, et al., 
2005). The analysis performed in this study could confirm a great variability in Ig 
gene features and usage among such patients. All the analyzed DNA sequences of 
the 245 antibodies from the four SLE patients resulted from an independent V(D)J 
recombination. Massiv clonal expansion was therefore not a feature of SLE IgG+ 
memory B cells. The number of analyzed B cells, nevertheless, might have been too 
small to detect low levels of clonal expansion. A distinct CD38+CD27++ plasmablast 
population, previously linked to SLE disease activity, was only identified in one of the 
four SLE patients further underlining the great variability in SLE features (Arce, et al., 
2001; Jacobi, et al., 2003; Odendahl, et al., 2000; Vallerskog, et al., 2007). 
 
4.2 The IgH chain repertoire in SLE IgG+ memory B cells 
Significant differences in IgH gene usage were not found between the IgG+ 
memory B cells of SLE patients and HC and only observed in individual patients, 
such as an altered DH usage in SLE174 and VH usage in SLE169. Previously ob-
served differences such as an increased VH3 usage could not be confirmed and 
might have resulted from a broader selection on IgD- B cells or from the limited num-
ber of sequences analyzed in those studies (Odendahl, et al., 2000; Pugh-Bernard, et 
al., 2001). 
A long IgH chain CDR3 has been associated with self- and polyreactivity, due 
to a greater flexibility in the protein structure of the ag-binding domain, which would 
result in decreased specificity (Crouzier, et al., 1995; Ichiyoshi and Casali, 1994; 
Klonowski, et al., 1999). Analysis of antibodies cloned from human progenitor B cells 
showed that the CDR3 length was significantly increased in these highly polyreactive 
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B cell compartments as compared to less polyreactive later developmental B cell 
stages (Wardemann, et al., 2003). The CDR3 length of SLE IgG+ memory B cells was 
not significantly different from HC, confirming an earlier study (de Wildt, et al., 2000). 
When analyzing the polyreactive SLE antibodies, the average IgH CDR3 length was 
significantly increased compared to that of the non-polyreactive SLE antibodies. This 
could, however, not be confirmed for the HC antibodies. Therefore, CDR3 length 
alone might enhance, but it does not determine polyreactivity. 
A second feature of IgH chain CDR3s that has been suggested to predispose 
B cells for self-reactivity is the presence of charged aa. In SLE, especially the role of 
positively charged aa in DNA-binding has been investigated (Eilat, et al., 1988; Li, et 
al., 2000; Radic, et al., 1993). Arginine residues, for example, enhance the specificity 
to dsDNA by binding within the major groove of the DNA backbone (Seeman, et al., 
1976). IgG+ memory B cells from SLE patients exhibited no significant difference in 
the number of positively or negatively charged aa in their CDR3s in comparison to 
HC, confirming the results of an earlier study (de Wildt, et al., 2000). Nevertheless, 
these features primarily applied to strongly anti-dsDNA specific antibodies that were 
not found among those cloned from SLE IgG+ memory B cells in this study. 
Certain VH gene family members have been attributed to intrinsic self-
reactivity such as VH4-34 or VH3-23 and have been reported to be predominantly 
found in autoantibody-expressing B cells (Leucht, et al., 2001; Pugh-Bernard, et al., 
2001). Based on this observation, studies have been performed using anti-idiotypic 
specific antibodies as a way to determine self-reactivity (Cambridge, et al., 2008; 
Cappione, et al., 2005; Isenberg, et al., 1993). Nevertheless, a detailed analysis of 
IgVH gene usage in systemic autoimmune diseases already led Dörner et al. to the 
conclusion that there is no intrinsic autoreactivity within special VH gene segments 
and no specific VH gene segment selection (Dorner and Lipsky, 2001). Except for an 
overrepresentation of VH4-4, which was only found in patient SLE169, no differences 
in the expression of single VH gene segments could be observed between HC and 
SLE. Further, the frequency of self-reactive B cells expressing either VH4-34 or VH3-
23 is comparable to the level of self-reactivity generally found in IgG+ memory B cells 
of SLE patients and HC (33% in VH4-34 or VH3-23 expressing B cells vs. 30% in 
SLE and 33% in HC; Figure 17 and SI: Table 5-9; (Tiller, et al., 2007)). Determining 
antibody reactivity based on idiotype alone might be misleading and should be con-
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sidered carefully, especially in the case of analyzing somatically mutated B cells 
since mutations can interfere with the binding of anti-idiotypic antibodies (Zheng, et 
al., 2004). It should further be mentioned that those earlier reports analyzed the VH 
gene usage of autoreactive B cells and did not give a general overview on the B cell 
repertoire in SLE. 
 
4.3 The IgL chain repertoire in SLE IgG+ memory B cells 
The analysis of the SLE Igκ L chain repertoire revealed an increase in Vκ2 
usage, confirming an earlier study which also found an enhanced expression of Vκ2 
gene family members in IgG+ memory B cells of SLE patients (de Wildt, et al., 2000). 
Vκ3 usage was further decreased in SLE IgG+ memory B cells, particularly the usage 
of Vκ3-20. Similarly, mature naïve B cells from untreated active SLE patients showed 
a lower frequency in Vκ3-20 usage than HC, but this did not reach statistical signifi-
cance (Herve, et al., 2007; Wardemann, et al., 2003; Yurasov, et al., 2005). Thus, it 
remains to be determined whether alteration in V(D)J recombination or selection are 
responsible for these differences. 
The Igλ L chain repertoire of SLE IgG+ memory B cells was comparable to 
HC. Changes in the Igλ L chain repertoire observed in an earlier study of a single 
SLE patient could not be confirmed (Dorner, et al., 1999). This might be due to indi-
vidual variations only present in this particular SLE patient. Changes in Igλ gene us-
age were further not observed in a more recent study on SLE IgG+ memory B cells 
and are therefore not a frequent feature (de Wildt, et al., 2000). 
In general, the B cell repertoire can even vary strongly within the same indi-
vidual (Yurasov, et al., 2006). Yurasov et al. observed significant changes when com-
paring the repertoire of SLE patients during active disease with that of the same indi-
viduals during clinical remission. 
 
4.4 Secondary rearrangement in SLE IgG+ memory B cells 
Receptor editing has been proposed to be the dominant mechanism in estab-
lishing self-tolerance and is mainly achieved by secondary rearrangement on the light 
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chain locus. Impairment in secondary IgL chain rearrangement in SLE and other sys-
temic autoimmune diseases has been suggested to participate in the generation of 
autoantibodies (Bensimon, et al., 1994; Dorner, et al., 1998; Samuels, et al., 2005; 
Suzuki, et al., 1996; Yurasov, et al., 2006). While a reduction could impede mecha-
nisms normally leading to the elimination of self-reactive receptors, an increase was 
proposed to participate in the formation of new self-reactive specificities because de-
letion by further rearrangements would no longer be possible (Zouali, 2008). In SLE 
IgG+ memory B cells, an alteration in secondary rearrangement could not be ob-
served in the analysis of Vκ to Jκ and Vλ to Jλ gene segment joining in comparison 
to HC. A major defect in secondary rearrangement is therefore not a common feature 
of SLE IgG+ memory B cells. There was further no evidence for differences in V(D)J 
recombination between SLE IgG+ memory B cells and HC when analyzing the joining 
of VH to JH gene segments. 
 
4.5 Increased Igλ L chain usage in SLE IgG+ memory B cells 
Evidence for the role of Igλ as an editing L chain, that eliminates undesired 
specificities by replacing the Igκ L chain of a self-reactive B cell receptor, comes from 
observations in mice (Retter and Nemazee, 1998). Retter et al. found that 47% of all 
Igλ L chain expressing murine B cells contain a productively rearranged Igκ locus 
(Retter and Nemazee, 1998). In humans, the Igκ L chain locus is likewise rearranged 
before the Igλ L chain locus, and approximately 60% of human B cells express Igκ 
(Goossens, et al., 2001; Hieter, et al., 1981; Szczepanski, et al., 2000; Wardemann, 
et al., 2004). In patient SLE169, the Igλ L chain antibodies of Igκ+Igλ+ double ex-
pressing B cells exhibited autoreactivity only in concordance with the respective Igκ L 
chain antibody, and in vivo experiments showed that Igλ is more effective than Igκ in 
silencing self-reactive IgH chains (Wardemann, et al., 2004). All four SLE patients 
showed a relative increase in Igλ L chain usage. The increase in Igλ L chain express-
ing B cells in SLE might result from extensive receptor editing either through in-
creased stimulation of an overactive immune system or as an attempt to eliminate 
self-reactive receptors. 
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4.6 Allelic inclusion in SLE IgG+ memory B cells 
Only one patient, SLE169, showed a high frequency of Igκ+Igλ+ double posi-
tive cells. Allelic inclusion can silence autoantibodies by diluting out autoreactivity. 
This mechanism allows B cells that produce self-reactive antibodies to pass the cen-
tral self-tolerance checkpoint and to participate in immune responses (Casellas, et 
al., 2007; Doyle, et al., 2006; Gerdes and Wabl, 2004; Li, et al., 2004; Liu, et al., 
2005; Velez, et al., 2007; Witsch, et al., 2006). In patient SLE169, one third of the 
antibodies of Igκ+Igλ+ double expressing B cells exhibited autoreactivity only with the 
respective Igκ L chain. Allelic inclusion thus contributed to the presence of IgG+ 
memory B cells expressing self-reactive antibodies. Double producing B cells were 
rare in the IgG+ memory B cell pool of the other SLE patients and were not enriched 
in naïve B cells from untreated SLE patients with active disease (Yurasov, et al., 
2006; Yurasov, et al., 2005). Thus, isotypic inclusion is not a frequent feature of this 
disease. Nevertheless, it may be characteristic of a subgroup of SLE patients where 
it contributes to the presence of self-reactive B cells. 
 
4.7 Somatic mutations and selection in SLE IgG+ memory B cells 
IgG+ memory B cells from SLE patients showed overall significantly reduced 
numbers of IgH and IgL chain SHM. IgV gene R to S ratios in FWRs and CDRs were 
normal, suggesting that selection of activated B cells is not grossly affected. Others 
have reported an increase in Ig mutational frequency in peripheral CD19+ B cells in 
SLE (Dorner, et al., 1999; Dorner and Lipsky, 2001; Jacobi, et al., 2000), including 
skewed R to S ratios (Dorner, et al., 1999). These findings were not confirmed in an-
other study on circulating IgG+ B cells, where, in fact, SHM frequency was found to 
be slightly lower in patients as compared to HC (de Wildt, et al., 2000). On average, 
the number of VH gene mutations was generally higher than in IgVL chain genes in 
SLE and HC and comparable to the values reported by others (Brezinschek, et al., 
1998; de Wildt, et al., 1999; de Wildt, et al., 2000). Only patient SLE169 exhibited an 
increased IgVH to IgVL chain mutation ratio. The mutational frequency in Igλ L chain 
genes was lower than in Igκ L chain genes, as also observed by others (Tiller, et al., 
2007). 
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4.8 IgG isotype subclass distribution was shifted in three SLE 
patients 
A shift in the distribution of the IgG isotype subclasses was found in the IgG+ 
memory B cells from three of the four SLE patients. Altered IgG subclass frequencies 
have previously been noted in the sera of SLE patients (Oxelius, 1984; Tokano, et al., 
1988). Since the shift in IgG isotype subclasses was neither consistent in the IgG+ 
memory B cells of the four patients considered in this study, nor in the SLE sera ana-
lyzed in the earlier reports, it is not a frequent feature of SLE. 
A reduction of complement C3 and C4 was observed in two of the patients 
(SLE169 and SLE176), who also exhibited the highest levels of IgG3. IgG3 is the 
strongest activator of complement among Ig isotypes (Bindon, et al., 1988). The shift 
in IgG subclass distribution was observed in IgG+ memory B cells and their participa-
tion to antibody serum titers is not known. Yet, a strong correlation between memory 
B cells and antibody serum titers has been observed (Bernasconi, et al., 2002). A 
possible link between a shift in IgG isotype subclasses and the often reported re-
duced levels of complement components in SLE should be further investigated. 
 
4.9 Polyreactivity in SLE IgG+ memory B cells 
Due to a defect in early B cell self-tolerance checkpoints, patients with SLE 
show high numbers of circulating self-reactive and polyreactive mature naïve B cells 
(Yurasov, et al., 2006; Yurasov, et al., 2005). Polyreactive and self-reactive B cells 
can be recruited into germinal center reactions and contribute to the formation of 
autoreactive plasma cells and memory B cells. However, the frequency of self- and 
polyreactive IgG+ memory B cells in SLE was comparable to HC and suggests that 
the increased number of self-reactive naïve B cells does not have a strong impact on 
the general level of autoreactivity in the IgG+ memory B cell pool. The reversion ex-
periments performed in this study further showed that self-reactive B cells mostly 
originated from non-reactive precursors. Thus, the defects that lead to abnormalities 
in IgG+ memory B cell tolerance in SLE may be independent of the earlier defects in 
tolerance. Nevertheless, it seems possible that certain autoantibody specificities are 
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more easily generated from a larger pool of self-reactive naïve B cells or directly se-
lected into the antibody-secreting plasma cell pool. 
 
4.10 Autoreactivity in SLE IgG+ memory B cells 
IgG autoantibodies with high levels of reactivity for SLE autoantigens Ro and 
La were only identified in patient SLE175, where they made up a substantial fraction 
of the circulating IgG+ memory B cell pool. Because of the relatively small number of 
cloned antibodies from the other patients it is not possible to determine whether 
autoreactive memory B cells were infrequent or simply not circulating in the blood 
streams of these patients. 
Ro- and La-reactive autoantibodies from patient SLE175 were highly mutated, 
and similar to low-level self-reactive and polyreactive antibodies from healthy donors, 
reversion to their germ-line form left them less or non-reactive, suggesting a competi-
tive selection process. These observations are consistent with previous analyses 
showing that anti-DNA autoantibodies from SLE patients and mice acquire their reac-
tivity through somatic mutations and are products of selection (Cocca, et al., 2001; Li, 
et al., 2003; Radic and Weigert, 1994; Wellmann, et al., 2005). Of all the reverted 
antibodies, only a few showed self- and polyreactivity independently of somatic muta-
tions, confirming the results of previous reversion experiments (Herve, et al., 2005; 
Tiller, et al., 2007; Tsuiji, et al., 2006). 
 
4.11 The role of memory in SLE 
Within the past years, B cell depletion therapy applying the chimeric mono-
clonal anti-CD20 antibody Rituximab, originally developed against B cell lymphomas, 
has become an alternative approach in the treatment of autoimmune diseases. Due 
to the broad target molecule expression in the B cell linage, it does not only deplete 
malignant but also normal B cells and has therefore been applied to patients that 
were nonresponsive or poorly responsive to conventional immunosuppressive ther-
apy (Lu, et al., 2009; Tokunaga, et al., 2005). Responses to Rituximab treatment are 
variable. Some patients experience long-term clinical remission, while others exhibit 
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only short clinical remission or no response at all (Anolik, et al., 2004; Anolik, et al., 
2007; Looney, et al., 2004). Studies on the dynamics of the repopulation of circulating 
B cells after depletion therapy have emphasized the role of memory B cells in sys-
temic autoimmune diseases. In SLE and RA, the reappearance of high numbers of 
circulating CD27+ memory B cells has been correlated with a higher relapse rate and 
a limited time of clinical remission (Anolik, et al., 2007; Leandro, et al., 2006). It could 
however not be determined whether this was due to a fast regeneration or an efflux 
of nondepleted memory B cells from secondary lymphoid organs. In animal studies 
on cynomolgus monkeys and mice transgenic for human CD20, B cell depletion in 
lymphoid organs is not complete after Rituximab-treatment and varies between indi-
viduals, even if the same dose is applied (Gong, et al., 2005; Reff, et al., 1994; 
Schroder, et al., 2003). For humans, it has also been concluded that memory B cells 
persist in solid lymphoid tissue, where they survive depletion therapy (Pers, et al., 
2007). Varying effects on B cells during ablative therapy is evident by a discrete re-
sponse of certain autospecificities. While anti-DNA is readily depleted from serum 
anti-Ro is not (Isenberg, et al., 1997; Leandro, et al., 2005; Ng, et al., 2007). Since B 
cell depletion therapy acts on structures independent of the variable region of the 
BCR, it is unlikely that B cells vary in their susceptibility to immunoablative therapy 
solely due to their receptor specificity, but rather that B cell responses differ accord-
ing to certain self-antigens, for example due to differences in antigen-presentation. 
These findings therefore suggest that certain autoantigen-specific B cells arise 
through different mechanisms, are predominantly selected into different B cell com-
partments, or reside at different locations within the body. 
The presence of baseline ENA, including Ro52 and La, further correlates with 
a faster reappearance of circulating CD27+ memory B cells after B cell depletion in 
SLE patients and thus a higher risk of relapse after treatment (Anolik, et al., 2007; 
Ng, et al., 2007). Therefore, autoantibody specificities should be considered in the 
decision on treatment. Since patients with a prolonged clinical remission were limited 
in their baseline autoantibody repertoire but anti-DNA positive, conventional markers 
in SLE such as anti-DNA titers, might be less relevant for disease severity and pro-
gression. Instead, the presence of certain specificities such as anti-ENAs should be 
taken more into account for the design of future therapies. 
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Continuous autoantibody titers, including anti-ENA, after B cell ablative ther-
apy have been suggested to result from long-lived PCs, which do not express CD20 
and are not depleted by standard therapy (Alexander, et al., 2009). Autologous stem 
cell transplantation has shown to induce remission in SLE, but it is only applied in 
severer cases due to the high mortality (Jayne, et al., 2004). Approaches especially 
targeting long-lived PCs have been undertaken in mice with the proteasome inhibitor 
Bortezomib (Neubert, et al., 2008). It decreases disease activity, even if application 
follows disease onset, and clinical trials for the application on human patients are on 
the way. Nevertheless, it can not be excluded that long-lived PCs are replenished by 
activated memory B cells that survived B cell depletion and reoccupy empty niches of 
depleted plasma cells. Memory B cells readily respond to activation by differentiation 
into antibody secreting B cells (Arpin, et al., 1997; Bernasconi, et al., 2002; Lan-
zavecchia, et al., 2006; Tangye and Good, 2007). This might especially be the case 
in an overactive immune system such as in SLE and with less competition for survival 
factors after depletion therapy (Desai-Mehta, et al., 1996; Lipsky, 2001). 
 
4.12 Conclusion and outlook 
The sequential analyses of the different B cell populations according to devel-
opmental stages would require a detailed analysis of the SLE plasma cell compart-
ment as a next step. Antibody-secreting plasma cells reside in the bone marrow and 
should be the direct link to SLE serum autoantibodies titers. Single plasma cells from 
the bone marrow of SLE patients could be sorted and examined according to the 
method applied in this study. 
In the present study, anti-Ro and anti-La antibodies were identified at high fre-
quency within the IgG+ memory B cell compartment in one SLE patient. Anti-Ro and 
anti-La autoantibodies have been described as a marker for risk of congenital heart 
block in newborns of seropositive mothers (Lee, et al., 1994; Salomonsson, et al., 
2002). Inhibitory effects have been confirmed in vitro on rat cardiomyocytes 
(Salomonsson, et al., 2005). For many SLE-associated autoantibody specificities, a 
role in pathogenesis has not been identified, which could enable a more directed 
from of treatment. 
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Possible ways of memory B cell activation and differentiation have further 
been discussed. Their contribution to antibody serum titers however, remains a sub-
stantial question. 
Numerous checkpoints in B cell development have been identified (Tsuiji, et 
al., 2006; Wardemann, et al., 2003). In HC, self- and polyreactivity is increased in the 
IgG+ memory B cell compartment as compared to mature naïve B cells, suggesting 
no further checkpoint. Nevertheless, highly self-reactive B cells were found in one 
SLE patient. The question remains whether a checkpoint exists, excluding only highly 
self-reactive B cells from progressing into the IgG+ memory pool in healthy individuals 
that is defective in SLE patients, or whether another predisposition is required for the 
generation of highly self-reactive B cells in SLE. For this, a detailed analysis of GC B 
cell subsets would be necessary that compares the reactivity of B cells that acquired 
somatic mutations instantaneously, but were not yet subjects to possible selection 
mechanisms, with unmutated B cells and those about to leave the GC. 
The lack of anti-DNA specific autoantibodies in the IgG+ memory B cell com-
partment raises the question if B cells are recruited into different compartments ac-
cording to specificities, for example due to differences in antigen presentation. Since 
it is not possible to monitor this question within humans, it would be thinkable to im-
munize for example mice with structurally different antigens and afterwards assess 
different B cell compartments for the presence of ag-specific B cells. 
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Supplemental figures 
 
Figure 21: IgH chain V, D, and J gene usage and CDR3 region features of IgG memory B cell 
antibodies from healthy controls and SLE patients. IgH chain gene repertoire and CDR3 fea-
tures of antibodies from IgG+ memory B cells of one HC donor (JH) and four patients with 
SLE (SLE169, SLE174, SLE175, SLE176). P-values are in comparison to combined data 
from HC-JH and three additional previously published healthy controls (Tiller 2007). (A) Pie 
charts depict V, D, and J family usage and (B) the proportion of IgH CDR3s with 0, 1, 2, or ≥ 
3 positive charges. Bar graphs show frequencies of IgH CDR3s with ≤ 9 aa (white bars), 10–
14 aa (light gray bars), 15–19 aa (dark gray bars), and ≥ 20 aa (black bars). The absolute 
number of sequences analyzed is indicated in the center of each pie chart. Average IgH 
CDR3 aa length is indicated above the bar graphs. 
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Figure 22: IgL chain V and J gene usage of IgG memory B cell antibodies from healthy 
controls and SLE patients. Pie charts depict Vκ/Jκ (A) and Vλ/Jλ gene family usage (B) of 
antibodies from IgG+ memory B cells of one HC donor (JH) and four patients with SLE 
(SLE169, SLE174, SLE175, SLE176). P-values are in comparison to combined data from 
HC-JH and three additional previously published healthy controls (Tiller 2007). The absolute 
number of sequences analyzed is indicated in the center of each pie chart. 
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Figure 23: VH gene usage in IgG+ memory B cells of healthy donors JH, HW, PN, and VB. The frequency of individual VH genes is shown for 
each individual. 
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Figure 24: VH gene usage in IgG+ memory B cells of SLE patients 169, 174, 175, and 176. The frequency of individual VH genes is shown for 
each individual. 
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Figure 25: Vκ gene usage in IgG+ memory B cells of healthy donors JH, HW, PN, and VB. The frequency of individual Vκ genes is shown for 
each individual. 
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Figure 26: Vκ gene usage in IgG+ memory B cells of SLE patients 169, 174, 175, and 176. The frequency of individual Vκ genes is shown for 
each individual. 
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Figure 27: Vλ gene usage in IgG+ memory B cells of healthy donors JH, HW, PN, and VB. The frequency of individual Vλ genes is shown for 
each individual. 
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Figure 28: Vλ gene usage in IgG+ memory B cells of SLE patients 169, 174, 175, and 176. The frequency of individual Vλ genes is shown for 
each individual. 
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Figure 29: Number of somatic hypermutations in individual SLE patients and healthy 
controls. Dots depict individual VH, Vκ, and Vλ genes of healthy controls and SLE patients. 
Pooled data from healthy donors (Total HC) and SLE patients (Total SLE) is shown for com-
parison. Horizontal lines represent the average number of mutations in each individual. VH 
and Vκ genes of Ro and La specific antibodies from SLE175 are depicted in red and num-
bers indicate the respective antibody. 
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Figure 30: Vector maps of the applied eukaryotic expression vectors. Maps show the 
respective vectors for the cloning of IgH (yellow), Igκ (green), and Igλ (blue) chains. Restric-
tion sites are indicated. 
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Supplemental tables 
Table 5: Ig gene usage and features of antibodies cloned from single IgG+ 
memory B cells of patient SLE169 
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Ig HEAVY LIGHT REACTIVITY
gm/gp169 VH D RF JH V-Mut. CDR3 (aa) Length SC Vκ Jκ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
gm169-3κ 3-48 3-3 2 6 40 EDDFWSGVYQTDYRFYPVDV 20 IgG1 3-20 1 0 QQYGSSPWT 9 / / / / /
gm169-15 1-24 1-26 3 3 2 DRVEVGATEAFDI 13 IgG1 3-11 4 1 QQRSNWLLT 9 / / / / /
gm169-16κ 1-8 / / 6 8 RGSTVYYYYYGMDV 14 IgG1 1-33 5 0 QQYDNLSS 8 / / / / /
gm169-20κ 3-7 3-22 2 4 6 APPGSGSEYYFDY 13 IgG2 4-1 2 4 HQYYSSPYT 9 / / / / /
gm169-22κ 3-23 2-2/15or3-22 2 4 22 DSCGSPTCRTRYHSFDY 17 IgG1 3-15 2 6 QQYNRWPPHT 10 / / / / +
gm169-24κ 4-4 3-3 2 5 14 GRDYDFWSGYSRQKEMYNWFDP 22 IgG3 2-28 2 3 MQALQTPYT 9 + + + + +
gm169-28κ 3-33 1-26 3 1 27 GNRLGATTFHH 11 IgG3 1-5 2 6 QQYKSLNT 8 + + + + +
gm169-31κ 3-66 3-22 1 3 8 GNGYYDSSGYWQRWDAFDI 19 IgG1 1-39 1 1 QQSYSTPWT 9 / / / / /
gm169-34κ# 4-4 2-15 2 3 15 ATEKYCRGGSCYFHDAFDI 19 IgG1 1-39 1 8 QQSYSTPRT 9
gm169-38κ 3-23 3-22 2 4 3 NIVNYYDSSGPLGY 14 IgG1 3-15 1 6 QQYNNWPRT 9 / / / / /
gm169-42 3-33 3-10 3 3 22 DANTVVRGVITPFDAFDL 18 IgG1 1-5 2 1 QQDRT 5 + + + + /
gm169-44 3-48 2-2 3 6 14 AKRDIVVIPAADGYYYYYYYMDV 23 IgG3 2-28 3 1 MQALQTPGT 9 / / / + /
gm169-46 4-39 5-24 2 3 24 QKDGYNPSDAFDV 13 IgG1 1-39 4 0 QQSYSTPLT 9 / / / / +
gm169-57 3-23 6-6 2 5 13 GRDHSSSTWFDY 12 IgG1 1-5 4 1 QQYNIYWLT 9 / / / / /
gm169-60 3-43 2-2 2 4 13 DLRFCSSMNCPTGFDY 16 IgG1 1-33 4 9 QHYDNVLT 8 / / / / /
gm169-61 4-39 / / 6 12 QEYTTSVYYYYMDV 14 IgG1 3-20 4 8 QQYGSSPLT 9 + + + + +
gm169-64κ 3-7 6-19 2 2 4 DYGLSYSSVVFSINWYFDL 19 IgG3 3-20 5 4 QQYGSSPIT 9 / / / / +
gm169-68 4-34 6-6or6-13 3 4 1 EKTRSSSSIAARKFGAAAGSGLFDY 25 IgG1 1-5 1 1 QQYNSYLTWT 10 + + + + +
gm169-70κ 3-13 3-10 3 4 1 GVMVRGVITYYFDY 14 IgG1 1-39 5 0 QQSYSTLIT 9 / / / + /
gm169-76κ 3-11 / / 6 2 DTPGRLVHYYYMDV 14 IgG1 2-28 2 6 VQALQTPYT 9 / / / / /
gm169-80κ 4-39 1-26 2 5 14 DLGGSSSFRF 10 IgG3 2-28 2 10 MQALQTPYT 9 + + + + +
gm169-86 4-4 2-21 2 4 6 RSYRGPFDY 9 IgG1 1-5 4 11 QQYNSYSSIT 10 + + + + +
gm169-94 3-30 3-10 2 4 27 GTGPGNYLTDY 11 IgG2 4-1 4 12 QQYYSAPLT 9 / / / / /
gm169-95 1-46 / / 4 24 DKEPKRPAQRTHYCDH 16 IgG1 1-39 4 15 QQSYTTRALT 10 / / / / /
gp169-8 1-24 3-22 2 3 0 VGDVYYDGALDI 12 IgG1 3-15 1 3 QQYNNWPWT 9 / / / / +
gp169-26κ 3-33 6-19 2 4 25 DRDSSGLYFLDY 12 IgG1 4-1 5 8 QQYYSSVT 8 / / / / /
gp169-29 4-4 2-2or3-10 3 5 6 DHLIVVVPAAMSRVGGFGELFPGWFDP 27 IgG1 3-20 3 2 QQYGSSPPT 9 / / / / /
gp169-53κ 4-4 / / 4 6 AQVYFDY 7 IgG1 4-1 3 16 QHYYSSPST 9 / / / / /
gp169-64κ 3-30 2-2 2 4 11 DWGGYCSSTSCSYFDY 16 IgG1 3-11 3 2 QQRFHWPRGIT 11 / / / + +
gp169-66 4-4 3-3 2 2 4 EGAYYDFWSGYYNLDWYFDL 20 IgG3 3-20 1 0 QQSGSSPT 8 / / + / +
gp169-81 5-51 3-3 2 3 17 GSTYYDSWNGPSDAFDI 17 IgG1 2-30 4 6 MQGTHWPLT 9 + + + + +
gp169-87 4-39 2-15 2 2 7 SHCSGDYCYSSWYFDL 16 IgG3 3-15 2 0 QQYNNWPRT 9 + + + + +
gp169-103κ 4-39 3-9 1 5 25 VFRYFDWLGWFDP 13 IgG1 4-1 5 11 QQYFSTPVT 9 + + + + +
gp169-108 1-2 / / 4 7 EQVITRDFDF 10 IgG1 2-28 2 3 MQALQIPRT 9 / / / / /
gp169-117# 4-59 3-3 2 3 6 VQGRSGPDDALDI 13 IgG1 1-5 2 6 QQYNSYSGYT 10
gp169-126 3-23 3-3 2 6 12 NNDFWSGYYEV 11 IgG1 3-15 1 2 QQYNNWPPWT 10 / / / / /
gp169-127κ 1-69 / / 4 9 DTGGGYFDY 9 IgG1 3-11 2 1 QQRSNWPPYT 10 + + + / /
gp169-129 5-51 4-23 2 2 5 PNYGGNHNYWYFDL 14 IgG1 1-12 4 3 QQANSFPYPLT 11 / / / / /
gp169-144κ 4-4 1-26 2 5 17 GPGSGNYFGGYDNWFDP 17 IgG2 1-6 5 9 LQDYNYPFT 9 / / / + /
gm/gp169 VH D RF JH V-Mut. CDR3 (aa) Length SC Vλ Jλ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
gm169-3λ 1-47 2 15 AAWDDSLSGVV 11 / / / / /
gm169-4 3-11 3-16or2-15 2 3 15 GGGTYSGAFDL 11 IgG1 2-23 3 8 CSYAGVSTFVV 11 / / / / +
gm169-8 4-34 2-15 1 6 16 GPRNSQLPLDYFYYYMDV 18 IgG2 1-47 2 14 AAWDDSLSGVV 11 + + + + /
gm169-11 1-2 / / 6 9 ERIQVTPRSYHYYYGMDV 18 IgG3 1-44 1 5 AAWDDSLIGSV 11 / / + / +
gm169-16λ# 2-11 1 ND CAYAGDHKWV 10
gm169-20λ 3-21 3 2 QVWDSSSDHPL 11 / / / / /
gm169-22λ 3-21 2 15 QVWDGIVV 8 / / / / /
gm169-24λ 9-49 1 1 GADHGSGSNFVYV 13 + + + + +
gm169-28λ 2-14 3 5 SSFTSSSTLAWV 12 + + + + /
gm169-31λ 3-25 2 1 QSADSSGTSVV 11 / / / / /
gm169-33# 4-34 6-19 2 5 18 DDSRAWVLDS 10 IgG3 2-14 1 15 GCYTGRSSYV 10
gm169-34λ 1-40 1 6 QSYDSSLSGYV 11 + + + + +
gm169-38λ 3-21 3 1 QVWDSSSDHQV 11 / / / / /
gm169-48 4-4 3-10or2-15 2 6 6 DVPTYCYGSGSCYSYIDV 18 IgG1 1-44 1 13 ATWDDSLNGFV 11 / / / / /
gm169-64λ 1-40 3 1 QSYDSSLGGSV 11 + + + + /
gm169-70λ# 1-40 3 0 QSYDSSLSGWV 11
gm169-74 1-46 2-15 2 4 14 AGYCTGGSCFLVY 13 IgG1 1-40 1 4 QSYDSSLSGSV 11 / / / / /
gm169-76λ 2-11 2 0 CSYAGSYTLV 10 / / / / /
gm169-80λ 3-21 2 5 QVWDSSSDHHVV 12 / / / / /
gm169-83 3-74 / / 4 8 DDDTFDY 7 IgG2 2-11 3 0 CSYAGSYTWV 10 / / / / /
gm169-85 3-48 1-26or5-12 2 5 12 GDSGIGP 7 IgG1 1-47 1 1 AAWDDSLSGPYV 12 / / / / /
gm169-88 3-30 2-15 2 4 9 SLSGGRCLRIDY 12 IgG1 3-1 2 7 QAWDTSTVV 9 / + / / /
gp169-23# 1-58 6-13 3 6 ND VNPPAAALMDV 11 IgG3 2-14 3 13 SSYTSGSTYWV 11
gp169-26λ 1-44 3 6 AAWDDSLNGPV 11 / / / / /
gp169-32 4-59 / / 6 9 DKAPKGMDV 9 IgG3 3-21 3 5 QVWDSSSDHPNWV 13 / / / / /
gp169-43 4-4 2-15 2 5 7 DWLNGYCSGGTCYSYWFDP 19 IgG3 1-40 2 0 QSYDSSLSVL 10 / / / / /
gp169-53λ 2-14 3 10 CSYTNSTTLGV 11 / / / / /
gp169-64λ 6-57 2 2 QSYDSSNVV 10 / / / / /
gp169-65 3-30 6-19 3 6 21 DERVAVAGMNYYYYYGMDV 19 IgG1 3-10 3 6 YSSDSSDKGV 10 / / / / /
gp169-71# 1-18 3-10 2 5 7 AVVGYGSGSYYPILVDY 17 IgG1 1-51 3 1 GTWDSSLSAGV 11
gp169-74 3-23 3-22 2 6 13 SKDYDIRGYYYVSPYHYGMDV 21 IgG3 3-1 3 2 QAWDSSSVV 9 + + + + +
gp169-77 3-33 6-19 3 4 5 DRGSSGLYYFDY 12 IgG1 6-57 3 2 QSYDSSNWV 9 / / / / /
gp169-82# 3-30 / / 6 10 DSVTPEAYYYYYGMDV 16 IgG1 1-47 3 8 AAWNDTLSGPNWV 13
gp169-83 3-23 3-3 3 6 9 SPSRGATIFGVATPYHCYMDV 21 IgG3 2-14 2 5 SSYTSTNTPVV 11 + + + + +
gp169-85 3-43 1-26 3 6 25 DGGYTTGYFMDV 12 IgG1 1-36 3 16 AAWDDSLSAWV 11 / / / / /
gp169-86 3-30 6-19 3 6 23 DQRIAVAGMNYYYYYGMDV 19 IgG1 3-10 3 10 YSTDTSDKGV 10 / / / / /
gp169-103λ 6-57 3 2 QSYDSSNWV 9 / / / / +
gp169-113 1-69 3-22 2 3 12 EKAKTYYYDSSGYPGGGALDI 21 IgG3 3-21 2 9 QVWESSSDLVV 11 + + + + /
gp169-116 3-30 3-10 3 6 14 DDGSGDYYYYAMDV 14 IgG1 1-40 3 9 QSYDSSLSGSWV 12 / / / / /
gp169-122 4-4 3-22 2 5 16 DRGYYYDGSDYQYNWFDP 18 IgG1 2-11 3 12 CSYAGTYTFWV 11 / / / / /
gp169-127λ 1-51 2 0 GTWDSSLSEGV 11 / / / / /
gp169-142 5-51 1-26 2 5 7 RSRESGSYSTWFDP 14 IgG1 1-44 3 2 AAWDDSLNGSWV 12 / / / / /
gp169-144λ# 2-8 3 5 SSYAGSFWV 9
gp169-148# 1-46 / / 6 21 QGSAWEGRLRSPAVVNSYGMDV 22 IgG4 6-57 2 5 QSYDSSPVV 9  
#, antibody was not expressed/tested; gm, IgG+ memory B cell; gp, IgG+ plasmablast; RF, DH gene reading frame; V-Mut., 
number of V gene mutations from FWR1 to CDR2, inclusively; SC, IgG isotype subclass; ss, ssDNA; ds, dsDNA; ins., insulin; +, 
reactive in ELISA/IFA; /, non-reactive in ELISA/IFA; ND, not determined 
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Table 6: Ig gene usage and features of antibodies cloned from single IgG+ 
memory B cells of patient SLE174 
Ig HEAVY LIGHT REACTIVITY
gm174 VH D RF JH V-Mut. CDR3 (aa) Length SC Vκ Jκ V-Mut CDR3 (aa) Length ss ds LPS ins. HEp2
174-2 4-39 4-17 2 6 11 HQHADGDYAYYYYYYGMDV 19 IgG1 2-28 1 1 MQALQMS 7 / / / / /
174-5 1-69 4-11/4 3 4 15 GLTTVTRFDY 10 IgG1 3-11 1 11 QQRSNWPPTWT 11 + + + + +
174-8 3-11 6-19 1 4 6 GGARGEQWLVLRY 13 IgG3 1-5 3 0 QQYDNPPS 8 / / / / /
174-9 1-2 3-22 2 5 12 GIYYDNFNGVGAHFDS 16 IgG1 4-1 4 4 QQYYGTPS 8 / / / / /
174-12# 1-46 / / 6 5 GYRDFGYGLDV 11 IgG1 1-27 5 2 QKYNSAPPAT 10
174-17# 3-23 6-13 1 5 4 GLQQLVRRGLDS 12 IgG1 2-29 3 2 MQSIQLPLFT 10
174-23 5-51 6-13 3 3 0 PAGIAAVDAFDI 12 IgG1 3-11 2 0 QQRSNWYT 8 / / / / /
174-24# 3-30 / / 4 5 DGPNGGLCDY 10 IgG2 3-20 4 4 QQYGSSLLT 9
174-28 3-23 6-13 2 5 15 DVPYGTTWYGRGDS 14 IgG2 1-39 4 13 EQTYSAPLT 9 + / / / /
174-32 3-49 3-3 2 3 10 RNAYYYDDAFAI 12 IgG2 1-5 2 3 QQYNSYSYT 9 / / / / /
174-35 1-46 / / 4 20 DGASNAWHIGY 11 IgG1 3-11 4 4 QHRINWRLT 9 / / / / /
174-55# 1-3 5-18/5 2 3 17 ERYAYGYAAFDI 12 IgG1 3-15 1 5 QQYNDWPPWT 10
174-60 5-51 6-19 3 5 19 RGDLAVAGTGFDP 13 IgG3 1-39 1 2 QQSYNTPWT 9 / / / / /
174-67 3-30 4-23 3 6 2 DLTTVDPSYYYYYGMDV 17 IgG2 1-6 1 0 LQDYNYPWT 9 / / / / +
174-79# 3-30 / / 4 15 DVGLGGDHWDYFDY 14 IgG1 1-39 5 5 QQSYSSPRIT 10
174-84 4-34 / / 6 3 LESMLEGLGYYYVMDV 16 IgG1 1-39 1 2 QQSYSTPWT 9 / / / / /
174-87 3-48 6-13 2 4 1 VGRTSPLYSSSWYGFDY 17 IgG1 3-20 3 0 QQYGSSPFT 9 / / / / +
174-91# 4-31 / / 4 0 DPPRATPFDL 10 IgG1 1-17 2 4 LQHNSYPYT 9
174-117# 4-34 6-13 3 4 8 GIAAFGY 7 IgG1 1-39 2 4 QQSYSTPRT 9
174-119 3-48 2-2 2 4 7 GGYCTSTSCHEPLFGVVMTIPRYFDY 26 IgG1 3-20 5 2 QQYGSSPT 8 / / / / /
174-120κ 1-24 / / 3 5 VTEGGRFDAFDI 12 IgG1 2-30 2 0 MQGTHWPMYT 10 / / / / /
174-129 3-30 2-15 2 5 17 GCSSSGNCFLIDY 13 IgG2 4-1 4 13 QQYYNSPLT 9 / / / / /
174-130 4-31 5-12 2 4 1 EGVYSAYPSAY 11 IgG1 3-11 3 1 QQRSNWPSFT 10 + + + + +
174-133 1-69 6-13 3 6 21 GIVAADYYGMDV 12 IgG4 2-28 2 4 MQSLQTSFT 9 / / / / /
174-140 4-59 / / 6 29 EDAYGMDV 8 IgG1 1-39 1 24 QQNDRAPRT 9 / / / / /
174-146# 3-72 3-22 2 4 9 LAGDGSGYYSIY 12 IgG2 3-20 4 12 QHFRGSPALT 10
174-148# 5-51 3-22 3 4 7 QGIVVPATWEGGFDY 15 IgG1 1-33 2 13 QQYGNLPCG 9
174-154 4-34 3-9 2 3 0 SAAYYDILTGYYADAFDI 18 IgG2 1-5 2 0 QQYNSYSPYT 10 + + + + +
174-156 4-39 2-2 2 4 14 RRQRGPDCSSTSCYFDY 17 IgG1 1-5 1 4 QHYDDFA 7 / / / / /
174-157# 3-53 6-19 2 4 6 VGYSSGWYRD 10 IgG1 3-15 1 4 QQYNNWPPGT 10
174-169# 3-23 3-22 2 6 15 DRSETSGSYSYYPSYYYLMDV 21 IgG2 1-5 1 11 QQYSTYSRT 9
174-176 3-23 / / 4 0 DGVRDSPSTFDY 12 IgG2 4-1 3 1 QQYYSTPPS 9 / / / / +
174-177 5-51 / / 6 5 PSAMDYYYAMDV 12 IgG1 3-20 1 2 QQYGSSPWT 9 / / / / /
174-179# 4-39 5-12 2 6 9 RYSGPVGFGLDV 12 IgG1 1-39 5 7 QQSYSSPRIT 10
174-184# 4-39 3-22 2 4 8 QDYYDSSGYSAFDY 14 IgG1 1-5 2 3 QQYNSYSPYT 10
174-194# 4-31 / / 4 11 GLTSFDY 7 IgG1 2-29 4 6 MQSIQLPLT 9
174-196 3-7 / / 3 23 DPEFSAFDI 9 IgG1 2-30 1 9 MQATHWPS 8 / / / / /
gm174 VH D RF JH V-Mut. CDR3 (aa) Length SC Vλ Jλ V-Mut CDR3 (aa) Length ss ds LPS ins. HEp2
174-1 1-69 3-22 2 6 9 GDYYASSGYYHGMDV 15 IgG1 3-10 2 3 YSTDSSGNHGV 11 / / / / /
174-16 4-28 / / 6 5 RVGYLDV 7 IgG1 2-23 3 12 CSYAGSGTWV 10 / / / / /
174-18# 5-51 2-15 3 5 4 GEVVAHNCFDP 11 IgG1 2-14 3 2 SSYTSSTLGV 10
174-29 3-15 3-22 2 3 13 EPLVEMYDFDI 11 IgG2 3-1 1 6 QAWDNSTARV 10 / + / / /
174-33 3-21 2-2 2 4 11 VRLGYCSNIRCAENKNFDF 19 IgG1 1-40 3 6 QSYDNKLRRV 10 + + + + +
174-44 3-33 3-16 2 4 22 GVWGNYPPDY 10 IgG1 2-23 3 12 CSYAGSRTWV 10 / + + / /
174-45 3-53 6-19 3 4 16 VLVQWLVPGNYFDY 14 IgG2 2-11 1 8 CSYAGTYTYV 10 + + / / /
174-54 4-59 2-15 2 2 13 RGTLGSCTGAHCATDWYFDL 20 IgG2 3-12 6 9 QAWDSSSDHPGV 12 + + + + +
174-59 3-33 / / 5 1 GEAWGTNWFDP 11 IgG3 2-23 2 1 CSYAGSSTPVV 11 / / / / /
174-63 3-74 / / 4 17 GHQPQYTKHFDY 12 IgG1 7-43 3 8 LLYFGGFWV 9 / / / / /
174-68 3-7 2-8 2 4 12 VRRDCTNGVCTYYFDY 16 IgG2 2-23 3 5 CSYAGSRNYWV 11 / / / / /
174-71 1-46 3-22 3 4 6 APGPVLITRPYYFDY 15 IgG2 2-23 3 8 CSYENSNIPNWV 12 + + + + +
174-77 3-15 3-9 1 4 6 DGNFDY 6 IgG2 2-8 3 4 SSYAGSNNVWV 11 / / / / /
174-82 5-51 4-23 2 4 19 THDGNFFWDY 10 IgG2 2-14 1 8 SSYTRTNTVTYV 12 / / / / +
174-114 1-18 3-10/3 3 5 22 DRVVRGPITGRNWLDP 16 IgG3 2-14 3 12 TSYTTSSTWV 10 + / + / +
174-115# 4-39 3-3 2 5 12 SKNDNDFWSAFATGWFDP 18 IgG1 2-14 2 3 SSDTSSTTLSG 11
174-118 4-59 3-22/9/3 2 3 14 VSAVEDGYWLVGAFDI 16 IgG1 1-44 2 5 AAWDDSLNGHVV 12 / / / / /
174-120λ 2-14 3 5 SSYTSSSTWV 10 / / / / /
174-125# 7-81 6-13 2 4 26 MMYSSSWNYFDS 12 IgG1 1-40 3 0 QSYDSSLSGSV 11
174-127 3-33 5-24 3 4 12 SRMTTFFLFDY 11 IgG1 6-57 3 3 QSYDSFNQV 9 / + / / +
174-131 4-28 / / 5 3 VKPVATFDY 9 IgG1 1-51 2 4 GTWDNSLSAGQ 11 / / / / /
174-151 3-53 6-13 3 4 5 GPFSAGNHYFDY 12 IgG1 3-1 2 2 QAWDNNTPV 9 / / / / /
174-162# 5-51 4-17 2 6 21 RRYGDHEGGLDV 12 IgG1 2-14 2 9 SSYTSDSTVI 10
174-165 3-53 1-26 2 3 13 GSTLVGDKGDAFDI 14 IgG1 2-14 2 6 SSYTSTNNLL 10 / / / / /
174-174 4-39 4-17 2 5 13 REDYGDYGWFDS 12 IgG1 2-23 3 10 CSYAGRSIM 9 / / / / +
174-180 5-51 4-17 2 4 12 HDEYGDF 7 IgG1 1-40 3 7 QSYDTSLSASL 11 / / / / +
174-183# 3-11 / / 4 23 GPGVTTVELDY 11 IgG1 1-44 2 10 STWDDSLVV 9  
#, antibody was not expressed/tested; gm, IgG+ memory B cell; RF, DH gene reading frame; 
V-Mut., number of V gene mutations from FWR1 to CDR2, inclusively; SC, IgG isotype sub-
class; ss, ssDNA; ds, dsDNA; ins., insulin; +, reactive in ELISA/IFA; /, non-reactive in 
ELISA/IFA; ND, not determined 
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Table 7: Ig gene usage and features of antibodies cloned from single IgG+ 
memory B cells of patient SLE175 
Ig HEAVY LIGHT REACTIVITY
gm175 VH D RF JH V-Mut. CDR3 (aa) Length SC Vκ Jκ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
175-19 3-23 3-22 2 5 15 QREYHYDSSDYDYEDS 16 IgG1 1-5 4 15 QQYLGYT 7 / / / / /
175-29 5-51 7-27 3 4 29 LPLTGGACDY 10 IgG1 3-15 1 14 QQYNKWWT 8 + + + + +
175-39# 3-43 2-21 2 4 17 PGGPFLMVGFFDN 13 IgG1 3-15 4 18 QQYNKGLT 8
175-62 4-61 3-10 2 5 17 DPGYGSGSYQIWFDP 15 IgG1 1-13 4 15 QQYYTTLLT 9 / / / / /
175-77 3-23 6-19 3 4 13 PASVAGQGGVDY 12 IgG1 1-5 1 9 QQYNTYFQWT 10 + + + + /
175-79 3-73 1-26 3 5 27 TSYVVGAPT 9 IgG1 2-28 4 8 MQALQTPLT 9 / + + / /
175-86# 3-23 2-21 3 4 14 GGVVVTAITFFDY 13 IgG1 3-15 1 0 QQYNNWPLWT 10
175-90 4-4 3-22 2 3 13 SLRDDYYDSSGYKTDAFDI 19 IgG1 1-5 1 2 QQYDTYSWT 9 / / / / /
175-95# 4-34 6-19 3 2 19 ATRVAVGIIGRVSYFDF 17 IgG3 1-39 5 20 QQSYTMRT 8
175-107 3-7 1-20/7 3 2 20 TARIAGTGGGYFDV 14 IgG1 1-5 2 13 QQYKSYT 7 / + / / +
175-108 1-69 2-15 2 4 5 SGGGYCSGGSCYSADY 16 IgG1 3-11 2 0 QQRSNWPPHT 10 / / + / +
175-113# 3-33 3-22 2 4 6 QGWPNYYDSSGYPSPVDY 18 IgG3 1-33 4 2 QQYDNLPPWLT 11
175-116 4-34 / / 4 8 KGWELLYFDY 10 IgG1 4-1 2 6 QQYYSTPYT 9 / / / / /
175-128 3-23 3-10 3 4 36 DGRRGFLRLVDYLDS 15 IgG1 2-28 1 12 MQALQTPPT 9 / / / / +
175-140 4-59 6-19 3 5 18 DRAVAAMYNWVDL 13 IgG1 1D-43 4 24 HQYYGTPLT 9 + + + + +
175-150# 1-18 3-10 3 4 3 SELRSTMVRGVIPRGRYFDY 20 IgG1 3-15 1 2 QQYNNWPET 9
175-153 3-7 / / 4 28 EVKSGTYFDF 10 IgG1 3-11 4 9 QQRINPLT 8 / / / / /
175-157 3-23 / / 4 27 EKVVVVPSALYLDY 14 IgG1 1-9 2 15 LQLNTNPYT 9 / / / / /
175-162 3-33 2-2 3 4 26 GQWGNWRENAVARHYYFDF 19 IgG1 1-5 1 16 QQYNSSSPT 9 / / + / +
175-217 1-8 6-19 2 4 8 GGGNSGWPTPYYFDN 15 IgG1 4-1 4 0 QQYYKAPSLT 10 / / / / /
175-229# 3-30 / / 4 29 GANTVRWDPVHFDN 14 IgG1 3-20 5 16 QQYGRSPIT 9
175-233 3-15 3-9 2 5 22 VQRGDILTEYCNS 13 IgG1 2-30 1 11 MQGTHWTWT 9 / / / / /
175-240 1-2 6-13 3 6 22 DSNIASPGIGTMDV 14 IgG3 1-39 4 14 QQTYSNPLT 9 / / + + +
175-241 4-31 6-13 2 4 6 LLTGSSSWYYFDY 13 IgG1 1-27 1 1 QKYNSAPWT 9 / / / / +
175-250 1-2 1-26 3 4 22 DRAIVGAANDFDY 13 IgG1 3-20 1 8 QQCGSSPT 8 / / / / /
175-258# 3-23 3-22 2 4 11 ERHYYDSSGGIDY 13 IgG1 1-16 4 6 QQYKSYPLT 9
175-260# 3-30 3-22 2 4 20 DGLYFDRSGFFFHFDH 16 IgG1 4-1 2 9 QQYYSAPPT 9
175-263# 1-8 / / 6 1 LQFEYSASYYGMDV 14 IgG1 3-15 4 3 QQYNNWPLT 9
175-264 3-33 6-19 2 1 14 DGGAYSSGWYPQH 13 IgG1 3-15 2 11 QQYNVRPYT 9 + + + / +
175-265 3-23 / / 4 13 RKTYYFDY 8 IgG1 3-11 5 5 QQRSDWPIT 9 / / / / +
175-266 3-15 6-19 2 4 1 VDSSVWYGHPIFDY 14 IgG3 3-20 1 4 QLYGISLWT 9 / / / / /
175-269 1-3 3-22 2 4 0 DGGPYYDSSGFGGADYFDY 19 IgG1 3-20 1 0 QQYGSSPGT 9 / / / / /
175-276 1-24 3-10 3 5 22 PYFSTSGSLGDLFDP 15 IgG1 2-40 1 14 KQRLDGVT 8 / / / / +
175-277 3-21 6-19/13 3 6 3 PVTPGIALYGVDV 13 IgG3 1-5 2 3 QQYNSDST 8 / / / / /
175-285# 3-9 / / 4 4 AAFGRLVGSGGLFDY 15 IgG1 2D-29 2 1 MQSIQLGYT 9
175-292# 1-69 4-17 3 3 0 RGGRGDYPYAFDI 13 IgG1 3-20 2 0 QQYGSSPYT 9
gm175 VH D RF JH V-Mut. CDR3 (aa) Length SC Vλ Jλ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
175-23 4-39 3-22 2 4 21 HVYHDSTTYYFSHYYFDS 18 IgG1 2-14 3 15 GSYTGNSSLYWV 12 / / + / +
175-42 3-74 / / 6 9 ELPGGYGMDV 10 IgG1 2-23 3 4 CSYAGSLTLV 10 / / / / /
175-80 4-34 3-10 2 3 0 GDYYGSRHAFDI 12 IgG1 2-11 3 0 CSYAGSYGWV 10 / / / / /
175-82# 1-3 4-17/11/4 2 5 4 GGRSSYRDDYGDYIVWFDP 19 IgG1 1-40 1 3 QSYDSSLSGYV 11
175-101# 4-39 6-19 3 6 13 TFPDYIAVAGPPRYYYGMDV 20 IgG3 1-47 1 0 AAWDDSLSAFYV 12
175-114# 1-3 / / 4 12 YISPEDPFDY 10 IgG1 2-23 1 6 CSYAGSSLYV 10
175-142# 4-31 / / 6 26 AGALRTVPYYYAMDV 15 IgG1 2-23 3 17 CSNAGGNIFLV 11
175-146# 4-34 3-10 1 5 20 GGGEGSFDS 9 IgG1 1-51 2 7 GTWDSSLSAVV 11
175-160 3-23 / / 4 8 DQAGSRLDY 9 IgG1 2-11 1 2 CSYAGTYTYV 10 / / / / /
175-165 3-23 5-18/5 1 3 10 DPPRWMQLWTTDAFDI 16 IgG1 1-44 1 2 ATWDDSLNGRV 11 + / / / /
175-169 1-8 5-18/5 2 4 1 AHFQRGYKDY 10 IgG1 1-47 2 0 AAWDDSLSGVV 11 / / / / +
175-215 4-28 3-10 2 4 12 NYGSGLYYFDY 11 IgG2 2-23 2 10 CSCAGSGTVV 10 / / / / +
175-236# 3-49 6-13 1 3 6 EQQLTSAHDVFDI 13 IgG1 3-21 2 4 QVWDSSSDHVV 11
175-238 1-2 4-17 3 6 10 DTVTTTYHYGLDL 13 IgG3 1-40 2 8 QSYDSSLRTVV 11 / / / / /
175-242 3-11 / / 4 5 AQGYFDY 7 IgG1 2-11 2 4 CSYAGSYTVV 10 / / / / /
175-248# 7-81 3-22 2 3 33 RGLHPYYYDTSGYSAFDI 18 IgG3 3-21 3 5 QVWDISSDHGV 11
175-249# 3-33 3-10 3 4/5 3 VKGYQRMTLVRGVINDY 17 IgG3 2-23 3 7 CSYAGSGTLW 10
175-270# 4-34 5-18/5 3 5 11 VDTAVVLEY 9 IgG3 1-51 3 6 GTWDSNLSAGV 11
175-280 3-48 4-17 2 6 12 EGYGDYLRYYAMDV 14 IgG1 2-23 1 10 FSYAGSSTFYV 11 / / / / /
175-282 3-74 1-26 2 4 8 LGGGSYPYFLDY 12 IgG1 3-1 2 8 QAWDSDTVV 9 / / / / /
175-286 4-61 / / 3 34 VENDSFDV 8 IgG2 2-23 3 27 CSYAGNKWV 9 / / / / /
175-289 3-11 / / 6 0 VMGGMDV 7 IgG1 2-11 3 0 CSYAGSFWV 9 / / / / /
175-295 3-9 6-13 2 4 3 GRLRSSTWGYFDY 13 IgG1 2-23 3 3 CSYAGSSTWV 10 / / / / +  
#, antibody was not expressed/tested; gm, IgG+ memory B cell; RF, DH gene reading frame; 
V-Mut., number of V gene mutations from FWR1 to CDR2, inclusively; SC, IgG isotype sub-
class; ss, ssDNA; ds, dsDNA; ins., insulin; +, reactive in ELISA/IFA; /, non-reactive in 
ELISA/IFA; ND, not determined 
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Table 8: Ig gene usage and features of antibodies cloned from single IgG+ 
memory B cells of patient SLE176 
Ig HEAVY LIGHT REACTIVITY
gm176 VH D RF JH V-Mut. CDR3 (aa) Length SC Vκ Jκ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
176-10 3-48 2-15 3 4 5 VAATGGSRFFDY 12 IgG1 1-33 5 2 QQYDNLPDT 9 / / / / /
176-62 3-23 2-2 2 5 8 EVEYCSSTSCNNSRGERWFDP 21 IgG2 3-15 2 0 QQYNNWRT 8 / / / / /
176-66 4-31 3-22 2 4 28 ESRPDRSGYYAFEF 14 IgG1 1-5 1 2 QQYNSYSRGT 10 + + + + /
176-91# 3-21 6-13 2 3 ND DRASHGSWTENAFAV 15 IgG1 1-5 4 18 QQYESYPLT 9
176-172# 3-21 3-9 1 4 1 AKLQYFDWLLSGPIDY 16 IgG1 3-15 1 0 QQYNSYSWT 9
176-214 1-69 3-22 2 4 0 SFPIRSYDSSGHFDY 15 IgG1 3-15 1 0 QQYNNWPPGT 10 + + + / /
176-236# 4-59 5-24 2 4 4 LDGYMPEGNYYFDY 14 IgG1 3-15 5 2 QQFNSYPIT 9
176-256 1-18 1-1/20 2 4 21 GSLNWKEGSVGY 12 IgG2 3-15 5 4 QQYNNWPPIT 10 / / / / +
176-267 3-23 3-22 2 3 8 DRRPSSDYYYDAFDV 15 IgG1 3-15 1 5 QQYDSYPGT 9 / / / / /
176-270 4-34 3-10or7-27 2/3 4 2 VSGWPGSYYITGSDNY 16 IgG1 3-15 2 0 QQYNSYPYT 9 + / + + +
176-301 3-33 / / 6 7 EPRARWYYGMDV 12 IgG2 2-28 2 4 MQALQTPHT 9 + + / / /
176-337 3-33 6-19 2 4 1 GEVEALKYSSGWTGALWDY 19 IgG3 2-28 1 0 MQALQTLWT 9 / / / / +
176-435 1-69 2-21 3 6 1 ASDIVVVTAYYYYYGMDV 18 IgG3 3-15 2 1 QQYNNWPPIT 10 + / / / +
176-514 1-69 4-23 3 6 3 DGGAGKSDVTPRGYYYYYMDV 21 IgG1 1-39 3 15 RQSYSTPVT 9 + / + / /
176-534 3-21 3-10 2 4 0 TAYYYGSGSYFGLYYFDY 18 IgG3 3-15 1 2 QQYNNWPPG 9 + / + / /
176-548 3-21 3-22 2 3 15 RYYYDSSSFDAFDI 14 IgG2 1-27 3 9 QKYDGAPFT 9 / / / / +
176-585 4-59 3-3 2 4 18 GISPYSRFWSGYKVHYFDY 19 IgG1 3-20 1 10 QQYGTSPGT 9 + + + + /
176-592# 4-31 3-3 3 4 2 VAIFGVVIIDY 11 IgG3 3-11 4 0 QQRSNWPQLT 10
176-611 3-9 2-2 1 4 1 DKYGNQLLSGPFDY 14 IgG3 4-1 2 3 QQYYSTPPT 10 + + + / +
176-618 1-58 3-22 2 6 2 DDRSADV 7 IgG1 3-11 5 1 QQRSNWPPGIT 11 / / / / /
176-621 4-34 2-2 3 6 17 EIVPPASYYYYIDV 14 IgG1 1-9 2 6 QQLNTYPRT 9 / / / / /
176-632 4-59 5-12 2 2 0 SRGYSGYDNLWYFDL 15 IgG3 4-1 3 0 QQYYSTPFT 9 / / / / /
176-641 3-23 6-19 2 4 8 VPGYSSGWFSDY 12 IgG2 3-15 1 3 QQYNNWPLA 9 / / / / /
176-650κ 3-9 1-26 2 5 6 DSSVYSGRYFGIDS 14 IgG3 4-1 4 5 QQYYSTPRLT 10 / / / / /
176-655 4-39 3-9 2 3 0 LSYDILTDPDAFDI 14 IgG3 3-15 2 0 QQYNNWPPMYT 11 / / / / /
176-694 3-48 / / 4 8 DPTRLRLRGYFDY 13 IgG3 1-39 1 2 QQSYSTPRT 9 / / / / +
gm176 VH D RF JH V-Mut. CDR3 (aa) Length SC Vλ Jλ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
176-29 3-48 2-15 3 4 6 VAATGGSRFFDY 12 IgG1 2-14 3 0 SSYTSSSTLV 10 / / / / /
176-130# 4-4 5-12 2 4 20 GYSSFSPDY 9 IgG1 1-44 3 ND ATWDDSLNGWV 11
176-223 4-34 2-2 3 5 0 DPIVVPAVGGWFDP 14 IgG3 1-40 2 0 QSYDSSLSAHVV 12 / / / / /
176-226 1-46 6-19 2 4 11 SYTSGWLYYLDF 12 IgG1 1-51 3 4 GTWDNSLSAGV 11 + + / + /
176-229 3-21 5-18 2 6 8 EGYSYGEHQGAMDV 14 IgG2 1-44 3 3 AAWDDSLNGRV 11 / / / / /
176-241 3-9 2-2/8 2 4 5 DMGHSRYTPRIDY 13 IgG2 2-14 2 0 SSYTSSSTHVV 11 / / / / /
176-253# 4-39 4-4/11 3 6 15 VDPTVTGLYYYGMDV 15 IgG1 1-40 2 3 QSYDSSLSGYVV 12
176-272 4-39 5-5/18 2 4 11 HRGYSYGDY 9 IgG1 3-9 3 1 QVWDSTSWV 9 + + + + +
176-275 1-8 2-2 2 4 1 GRRGYCNSTSCLYYFDY 17 IgG3 1-51 2 0 GTWDSSLSAVV 11 / / / / /
176-287# 1-2 6-13 3 5 10 DRPVDVTNPSGIWFDP 16 IgG1 1-40 2 3 QSYDSSLSDVL 11
176-290# 4-34 6-13 3 5 0 GASRDSTAKIAAAVDY 16 IgG1 2-14 3 2 SSYTSSSTRV 10
176-310 3-7 3-10 1 4 12 CGELLTSVPFDF 12 IgG1 1-47 3 7 ASWDDSLTSWV 11 / / / / /
176-318# 5-51 5-5/18or3-10 2 4 20 SVYTYGPVDY 10 IgG1 1-40 3 13 QSYDNSLSAKWV 12
176-323 1-69 3-22 2 3 0 GYDSSGYQIYAFDI 14 IgG2 2-14 1 2 SSYTSSSTLYV 11 / / / / /
176-365 4-31 5-24 3 3 9 GGVEMDGDAFDI 12 IgG1 3-21 2 2 QVWDSSSHRVI 11 / / / / /
176-392 4-4 / / 4 9 GKAFRYFDY 9 IgG1 2-14 3 2 SSYTSSNTLD 10 / / + / +
176-393# 4-61 3-10 2 5 30 ADDHGAGTHFYPGWFDP 17 IgG1 2-14 2 ND SSCMGLNTPVV 11
176-395 4-59 4-4/11 3 6 8 APTVTTYSYYYMDV 14 IgG1 3-21 2 4 QVWDSSSDHLVV 12 / / / / /
176-428# 1-18 3-3 3 4 0 DPGITIFGVVIIPVLYFDY 19 IgG1 2-14 1 5 SSYTSSNTYV 10
176-447# 4-59 2-2 3 6 3 ADIVAETDYYYYYMDV 16 IgG1 2-14 2 ND SSYTSSTTPYVV 12
176-508# 4-4 6-13 2 6 5 DSSSWPAVHMDV 12 IgG1 2-23 2 ND CSYVGSNVV 9
176-523 3-30 / / 6 12 GGSVPYYYYMDV 12 IgG1 1-51 1 2 GTWDNNLSAGV 11 / / / / /
176-535 3-11 6-13 1 3 0 AVTGLVQQLVFTTGARIDAFDI 22 IgG3 2-23 2 0 CSYAGSSTSVV 11 / / / / /
176-536 1-2 4-4/11/17 2 4 0 GVESSDY 7 IgG1 2-23 1 0 CSYAGSSTYV 10 / / / / /
176-540 3-30 3-22 2 6 5 SPPPYYYDSSGYRVDYYYMDV 21 IgG2 1-51 2 0 GTWDSSLSARV 11 / / / / /
176-558 3-48 6-19 3 4 8 GIALANSDFDH 11 IgG1 1-47 3 9 AAWDASLRGWV 11 / / / / /
176-614 4-39 5-5/18 3 4 0 RGWDTAMAQGYFDY 14 IgG1 1-44 3 0 AAWDDSLNGWV 11 / / / / /
176-616 3-9 3-22 2 3 2 DLYYDSSDYDAFDI 14 IgG1 1-44 2 1 AAWDDSLNGLV 11 / / / / /
176-620 3-9 2-8 2 3 13 PDCTNGVCSYGAFDI 15 IgG3 2-8 2 6 SSYAGNNIVL 10 / / / / /
176-627 3-30 2-2 2 4 33 GVFCPGTNCYWVGLPTN 17 IgG1 1-44 3 11 ASWDDSMRSPV 11 / / / / /
176-650λ# 4-69 2 ND QTWGTGIYVV 10
176-662# 3-30 / / 4 ND DHAQSWRSNYFDY 13 IgG3 1-51 2 0 GTWDSSLSAQV 11  
#, antibody was not expressed/tested; gm, IgG+ memory B cell; RF, DH gene reading frame; 
V-Mut., number of V gene mutations from FWR1 to CDR2, inclusively; SC, IgG isotype sub-
class; ss, ssDNA; ds, dsDNA; ins., insulin; +, reactive in ELISA/IFA; /, non-reactive in 
ELISA/IFA; ND, not determined 
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Table 9: Ig gene usage and features of antibodies cloned from single IgG+ 
memory B cells of healthy control JH 
Ig
gmJH VH D RF JH V-Mut. CDR3 (aa) Length SC Vκ Jκ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
JH1 1-18 5-12 3 4 12 DSGATMVPFY 10 ND 3-20 4 10 QQYGSSPLT 9 / / / / /
JH5 3-30 3-3 2 4 12 DLESYDFWSGLNDY 14 IgG1 3-20 1 7 QQYGRSQKT 9 / / / / /
JH17 4-34 5-12 3 4 15 WSVDIVTTTRGTKKNYFDD 19 IgG1 3-11 1 3 QQRSDWPKT 9 / / / / /
JH19# 4-59 5-12 2 4 6 MMPSGYVRV 9 IgG2 3-20 1 8 QQYGSTWT 8
JH20 3-33 3-9 1 6 12 DQPKGGSRYFDWLSADGMDV 20 IgG1 3-15 4 7 QQYNNWPPLT 10 + + + + /
JH22# 1-24 6-6 3 6 15 GGIAARPLYFYHALDV 16 IgG1 1-39 5 12 QQTYSAPLS 9
JH23# 1-18 3-10 3 6 13 DSLITLVREELLYYYHGMDV 20 IgG1 3-20 4 8 QQYGKSPRLT 10
JH-26# 5-51 4-23 2 4 14 SSHGGNSRSDY 11 IgG1 3-20 4 1 QQYAYSPLT 9
JH35 3-21 3-10 1 6 11 LLTWFGESIVDV 12 IgG1 1-6 4 6 LQDYNYPPLT 10 / / / / /
JH38 3-7 2-2 2 3 25 QYCTRTTCYTDAFDM 15 IgG2 1-39 2 24 QKSCGVPT 8 / / / / /
JH39# 3-30 3-22 2 3 26 GADTSGYSALDG 12 IgG1 1-39 3 16 QQSYSPPFT 9
JH40# 4-31 3-9 2 4 27 EARYYDLLTDSYSGGFDQ 18 IgG1 3-20 1 11 QQYGSSPRT 9
JH55 3-30 3-3 3 5 21 DGVQYFDIWSDYYSHNWFDP 20 IgG1 3-20 5 12 QHYGSTPPIT 10 / / + + /
JH56# 1-8 3-22 2 5 14 SLYYDRREYAAWFDS 15 IgG1 3-20 4 16 QQYGRSPLT 9
JH57 4-59 / / 5 20 FSVAGWFDP 9 IgG2 1-39 2 10 QQSYSTLGYT 10 / / / / /
JH60 3-23 3-10 1 5 11 SAGLLWFGNGNWFDP 15 IgG2 3-20 1 5 QQYGSLPST 9 + + + + /
JH65 1-18 5-12 3 3 21 DRRKDTVATLGEIDAFDV 18 IgG1 1-39 1 5 QQTFSRNT 8 / / / / /
JH66 3-48 / / 3 11 DKLPVSDAFDI 11 IgG1 1-39 4 7 QQSYSIPLT 9 / / / / /
JH69 3-7 2-15 2 1 7 GGGFLIEH 8 IgG2 4-1 5 10 HQFYGAPLT 9 / / / / /
JH76# 4-31 5-5/18 3 6 ND GLDTPMAYGMDV 12 IgG1 1-39 4 9 QQSYSHPN 8
JH78# 1-8 / / 5 13 GITWGWFDP 9 IgG2 3-15 3 10 QQYNDWPRT 9
JH81# 7-4 3-10 1 4 11 DRRGVLGELLYYFDY 15 IgG1 1-39 2 7 QQSYITPPV 9
JH82# 3-48 6-13 2 3 14 TYSASWYRGDAFDI 14 IgG1 1-9 1 5 QQLNSYPLWT 10
JH96 3-30 2-2 2 4 22 YNLEYCAGSICHAFDR 16 IgG1 3-15 2 5 QQYNDWPRT 9 / / / / /
JH101# 1-69 / / 4 25 DGSWINHRPSPFDY 14 IgG1 3-20 2 7 QVYGNSVHT 9
JH103 4-31 / / 5 27 YQDDEAIPRWFDA 13 IgG3 2-28 5 15 MQALQLPIT 9 / / / / /
JH113 3-33 / / 4 24 GSGGDYVPFDY 11 IgG1 1-5 1 15 QQYSTYAWT 9 / / + / /
JH114# 1-46 / / 4 14 DGDGTYASGY 10 IgG1 3-20 1 9 QQYGNSLWT 9
JH117# 3-23 3-22 2 4 14 STNYDSTGYYYAAGYYFEF 19 IgG1 3-20 1 14 QQYGSSPE 8
JH124# 4-39 6-19 2 5 ND LKYSDVWHETGFQC 14 IgG1 1-39 4 6 QQSYSAPLT 9
JH125# 3-9 3-16 3 4 15 RVIGAKYFDR 10 IgG2 1-12 4 7 QQTNTFPLT 9
JH129 1-18 3-10 3 6 15 SVRGVFMLNYDYYYGMDV 18 IgG1 1-33 4 9 QQYDNLPVT 9 / / / / /
JH131# 3-7 / / 4 17 TDTTNCGYFDS 11 IgG1 1-5 1 7 QQYNSYSLT 9
JH132 4-39 2-15 3 4 14 QAVAAAIIPVFYFDY 15 IgG1 1-39 5 17 HQTYGFPST 9 / / + + +
JH135 1-18 3-22 2 3 16 DRQYLDSRGDVLGAAFDI 18 IgG1 1-39 1 2 QQSFSTPGT 9 / / / / /
JH147# 3-30 5-12 2 6 9 PWRRGYSGYDNDVLDV 16 IgG1 3-20 2 3 QQYASSMYT 9
JH148 3-23 / / 5 17 NEGEYDYNWFDP 12 IgG1 1-5 1 5 QQSHSYSRT 9 / / / / /
JH154 3-33 3-9 2 6 7 APGDYDILAEEYYFYKMDV 19 IgG1 3-15 2 6 QQYNNWPYT 9 / + + + +
JH156 3-7 3-3 1 5 20 DKARLRFLEPSNWFDP 16 IgG2 1-27 5 12 QKYDRAPHS 9 / / / / /
JH160# 3-21 3-9 1 4 25 FRLRYLEWPHTDY 13 IgG1 3-20 4 9 HQYGFSSR 8
JH162 3-15 5-24 2 4 11 DGDVYNPFAY 10 IgG1 1-33 2 9 QQYDSLPYS 9 / / / / /
JH165 3-7 2-2 2 4 21 VQCTRTSCWGMLFFDH 16 IgG2 4-1 4 18 QQYYDFPLT 9 / / / / /
JH167# 4-59 / / 6 11 LTPPSFYSGMDV 12 IgG2 3-20 2 4 QQYGSSTGYT 10
JH179 3-23 6-19 2 2 21 VHASAWYLKWFFDL 14 IgG3 4-1 2 14 QQYSSTPYT 9 + + + + +
JH183# 3-11 3-16 2 4 11 DWGRGPD 7 IgG2 3-20 1 11 QYYGPSRRWT 10
JH186 1-2 3-10 2 4 9 GNYYGSGSDYYFDY 14 IgG1 1-39 4 14 QQSYGNPS 8 + + + + /
JH188 3-30 / / 5 10 CVGANCPNWFDP 12 IgG1 1-17 1 0 LQHNSYPWT 9 + + + + /
JH192 3-48 3-22 2 4 21 GPPYSY 6 IgG1 3-15 4 5 HQYNDWPLLT 10 / / / / /
JH194 7-4 / / 4 21 VQLGSRDFRADL 12 IgG1 1-5 1 17 QQYDNYSWT 9 / / + / /
JH195 4-34 5-24 2 6 21 QDGYNYGGGYYFYYGMDV 18 IgG1 3-20 1 11 QQCGSLPMT 9 / / / / /
gmJH VH D RF JH V-Mut. CDR3 (aa) Length SC Vλ Jλ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
JH16 4-39 3-22 2 4 5 HWYDSSGYYPAGRY 14 IgG1 1-47 2 6 AAWDDSLSAVV 11 / / / / /
JH21 3-15 3-3 3 4 21 SFGVIISDSFDY 12 IgG1 1-44 1 9 AAWDVSLRGPV 11 / + + / /
JH28# 3-74 2-21 3 3 16 LPFIVLMTEDASDI 14 IgG1 2-23 1 13 CSYAGTNTYV 10
JH42 7-4 / / 4 16 GTLNPPHFDY 10 IgG1 1-51 2 4 ATWDSSLSIVV 11 / / / / /
JH48# 5-51 2-15 2 4 15 RGYCGDVACFSVFDF 15 IgG1 1-40 2 9 QSYDSSLSGVV 11
JH50 4-31 / / 5 41 NIAPGRFDP 9 IgG2 2-23 3 19 CSYGGSFNWL 10 / / + / /
JH59# 1-2 / / 6 7 APQTPYYYYGLAV 13 IgG3 1-44 3 10 AAWDDSLNGWV 11
JH63 4-34 / / 4 33 GHVPRD 6 IgG3 1-47 3 16 AAWDDNLSGFWV 12 + + + + +
JH75 4-34 / / 4 4 GYYPTNDEEPHSKGRGPPFYFDY 23 IgG2 3-21 2 2 QVSDNTSDHPVV 12 / / / / /
JH79 4-31 / / 4 13 IPDFNKYHFDS 11 IgG1 2-14 2 7 SSYTTTSTLVI 11 / / / / /
JH88 3-66 / / 6 14 LKDWRWGHYSYYYGMDV 17 IgG1 1-44 2 7 AAWDDSLTGPV 11 / / / / +
JH91 3-21 6-19 2 4 16 VFSAWAFDF 9 IgG1 2-8 1 7 TSYAGNNDFV 10 / / / / /
JH93 4-39 1-1/20 2 4 15 HTWGAWNDPRRFYFDY 16 IgG1 3-1 2 13 QAWDSSTHVV 10 / / / / /
JH95 4-59 4-17 2 5 7 LSRENYDDYALFDP 14 IgG2 1-47 3 6 AAWDDSLSGPM 11 / / / / /
JH105# 4-4 3-16 2 4 40 ESYRSANHLWGTYQYVGIDY 20 IgG3 2-8 2 ND SSLAVSDNLI 10
JH107# 3-23 4-23 2 4 19 PIVPHGGNSGLDC 13 IgG2 2-14 2 ND SSYTSSTTL 9
JH109# 5-51 1-1/20 2 5 8 QLNWNDFGTNNRDSGWFDP 19 IgG1 2-14 2 16 SSHISGSTLVV 11
JH128 4-59 1-1/20 2 4 26 LNWNEFRFDH 10 IgG1 6-57 3 14 QSYHVRDWV 9 / / / / +
JH143# 5-51 / / 6 22 AAYDSVWVSGNYYYYYGMDV 20 IgG3 2-23 2 16 CSWAGSRNPVV 11
JH171 4-39 4-17 3 3 22 HGVTTDIAKPEIRDAFDF 18 IgG2 2-23 1 8 CSFAGYGTWV 10 / / / / /
JH185# 4-59 6-13 2 5 20 MRDSDTWFLNWFDP 14 ND 2-14 2 8 TSYTSSNTLVI 11
REACTIVITYLIGHTHEAVY
 
#, antibody was not expressed/tested; gm, IgG+ memory B cell; RF, DH gene reading frame; 
V-Mut., number of V gene mutations from FWR1 to CDR2, inclusively; SC, IgG isotype sub-
class; ss, ssDNA; ds, dsDNA; ins., insulin; +, reactive in ELISA/IFA; /, non-reactive in 
ELISA/IFA; ND, not determined 
SUPPLEMENTAL INFORMATION 
 86
Table 10: Ig gene usage and features of antibodies from B cells expressing 
kappa and lambda light chain 
Ig HEAVY LIGHT REACTIVITY
VH D RF JH V-Mut. CDR3 (aa) Length SC Vκ/λ Jκ/λ V-Mut. CDR3 (aa) Length ss ds LPS ins. HEp2
gm169-3κ 3-48 3-3 2 6 40 EDDFWSGVYQTDYRFYPVDV 20 IgG1 3-20 1 0 QQYGSSPWT 9 / / / / /
gm169-3λ 1-47 2 15 AAWDDSLSGVV 11 / / / / /
gm169-16κ 1-8 / / 6 8 RGSTVYYYYYGMDV 14 IgG1 1-33 5 0 QQYDNLSS 8 / / / / /
gm169-16λ# 2-11 1 ND CAYAGDHKWV 10
gm169-20κ 3-7 3-22 2 4 6 APPGSGSEYYFDY 13 IgG2 4-1 2 4 HQYYSSPYT 9 / / / / /
gm169-20λ 3-21 3 2 QVWDSSSDHPL 11 / / / / /
gm169-22κ 3-23 2-2/15or3-22 2 4 22 DSCGSPTCRTRYHSFDY 17 IgG1 3-15 2 6 QQYNRWPPHT 10 / / / / +
gm169-22λ 3-21 2 15 QVWDGIVV 8 / / / / /
gm169-24κ 4-4 3-3 2 5 14 GRDYDFWSGYSRQKEMYNWFDP 22 IgG3 2-28 2 3 MQALQTPYT 9 + + + + +
gm169-24λ 9-49 1 1 GADHGSGSNFVYV 13 + + + + +
gm169-28κ 3-33 1-26 3 1 27 GNRLGATTFHH 11 IgG3 1-5 2 6 QQYKSLNT 8 + + + + +
gm169-28λ 2-14 3 5 SSFTSSSTLAWV 12 + + + + /
gm169-31κ 3-66 3-22 1 3 8 GNGYYDSSGYWQRWDAFDI 19 IgG1 1-39 1 1 QQSYSTPWT 9 / / / / /
gm169-31λ 3-25 2 1 QSADSSGTSVV 11 / / / / /
gm169-34κ# 4-4 2-15 2 3 15 ATEKYCRGGSCYFHDAFDI 19 IgG1 1-39 1 8 QQSYSTPRT 9
gm169-34λ 1-40 1 6 QSYDSSLSGYV 11 + + + + +
gm169-38κ 3-23 3-22 2 4 3 NIVNYYDSSGPLGY 14 IgG1 3-15 1 6 QQYNNWPRT 9 / / / / /
gm169-38λ 3-21 3 1 QVWDSSSDHQV 11 / / / / /
gm169-64κ 3-7 6-19 2 2 4 DYGLSYSSVVFSINWYFDL 19 IgG3 3-20 5 4 QQYGSSPIT 9 / / / / +
gm169-64λ 1-40 3 1 QSYDSSLGGSV 11 + + + + /
gm169-70κ 3-13 3-10 3 4 1 GVMVRGVITYYFDY 14 IgG1 1-39 5 0 QQSYSTLIT 9 / / / + /
gm169-70λ# 1-40 3 0 QSYDSSLSGWV 11
gm169-76κ 3-11 / / 6 2 DTPGRLVHYYYMDV 14 IgG1 2-28 2 6 VQALQTPYT 9 / / / / /
gm169-76λ 2-11 2 0 CSYAGSYTLV 10 / / / / /
gm169-80κ 4-39 1-26 2 5 14 DLGGSSSFRF 10 IgG3 2-28 2 10 MQALQTPYT 9 + + + + +
gm169-80λ 3-21 2 5 QVWDSSSDHHVV 12 / / / / /
gp169-26κ 3-33 6-19 2 4 25 DRDSSGLYFLDY 12 IgG1 4-1 5 8 QQYYSSVT 8 / / / / /
gp169-26λ 1-44 3 6 AAWDDSLNGPV 11 / / / / /
gp169-53κ 4-4 / / 4 6 AQVYFDY 7 IgG1 4-1 3 16 QHYYSSPST 9 / / / / /
gp169-53λ 2-14 3 10 CSYTNSTTLGV 11 / / / / /
gp169-64κ 3-30 2-2 2 4 11 DWGGYCSSTSCSYFDY 16 IgG1 3-11 3 2 QQRFHWPRGIT 11 / / / + +
gp169-64λ 6-57 2 2 QSYDSSNVV 10 / / / / /
gp169-103κ 4-39 3-9 1 5 25 VFRYFDWLGWFDP 13 IgG1 4-1 5 11 QQYFSTPVT 9 + + + + +
gp169-103λ 6-57 3 2 QSYDSSNWV 9 / / / / +
gp169-127κ 1-69 / / 4 9 DTGGGYFDY 9 IgG1 3-11 2 1 QQRSNWPPYT 10 + + + / /
gp169-127λ 1-51 2 0 GTWDSSLSEGV 11 / / / / /
gp169-144κ 4-4 1-26 2 5 17 GPGSGNYFGGYDNWFDP 17 IgG2 1-6 5 9 LQDYNYPFT 9 / / / + /
gp169-144λ# 2-8 3 5 SSYAGSFWV 9
174-120κ 1-24 / / 3 5 VTEGGRFDAFDI 12 IgG1 2-30 2 0 MQGTHWPMYT 10 / / / / /
174-120λ 2-14 3 5 SSYTSSSTWV 10 / / / / /
176-650κ 3-9 1-26 2 5 6 DSSVYSGRYFGIDS 14 IgG3 4-1 4 5 QQYYSTPRLT 10 / / / / /
176-650λ# 4-69 2 ND QTWGTGIYVV 10
HW-174κ 7-81 6-13 2 6 2 THRLYNNSWFPLVYDMDV 18 IgG1 3-20 1 ND QQYGSSPRT 9 + + + + +
HW-174λ# 2-14 1 3 SSYTXTSTYV 10  
#, antibody was not expressed/tested; gm, IgG+ memory B cell; gp, IgG+ plasmablast; RF, DH 
gene reading frame; V-Mut., number of V gene mutations from FWR1 to CDR2, inclusively; 
SC, IgG isotype subclass; ss, ssDNA; ds, dsDNA; ins., insulin; +, reactive in ELISA/IFA; /, 
non-reactive in ELISA/IFA; ND, not determined; HW, previously published healthy control 
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Table 11: Ig gene usage, CDR3 aminoacid sequence and reactivity of mutated and respective unmutated germline IgG mem-
ory B cell antibodies from SLE patients after reversion of somatic mutations 
Ig HEAVY LIGHT REACTIVITY (mut) REACTIVITY (rev)
VH D RF JH V-Mut. CDR3 (aa) Reverted CDR3 (aa) Vκ/λ Jκ/λ V-Mut. CDR3 (aa) Reverted CDR3 (aa) poly HEp2 poly HEp2
gm169-8 4-34 2-15 1 6 16 GPRNSQLPLDYFYYYMDV GPRNSQLLLDYYYYYMDV λ 1-47 2 14 AAWDDSLSGVV AAWDDSLSGVV + + + +
gm169-28λ 3-33 1-26 3 1 27 GNRLGATTFHH ENRLGATTFQH λ 2-14 3 5 SSFTSSSTLAWV SSYTSSSTLAWV + / / /
gm169-61 4-39 / / 6 12 QEYTTSVYYYYMDV QEYTTSVYYYYMDV κ 3-20 4 8 QQYGSSPLT QQYGSSPLT + + / /
174-5 1-69 4-11/4 3 4 15 GLTTVTRFDY GLTTVTRFDY κ 3-11 1 11 QQRSNWPPTWT QQRSNWPPTWT + + + +
174-33 3-21 2-2 2 4 11 VRLGYCSNIRCAENKNFDF VRLGYCSSTSCAENKNFDY λ 1-40 3 6 QSYDNKLRRV QSYDSSLRRV + + / /
174-45 3-53 6-19 3 4 16 VLVQWLVPGNYFDY VLVQWLVPGNYFDY λ 2-11 1 8 CSYAGTYTYV CSYAGSYTYV / / + +
174-54 4-59 2-15 2 2 13 RGTLGSCTGAHCATDWYFDL RGTLGYCSGGSCATDWYFDL λ 3-12 6 9 QAWDSSSDHPGV QVWDSSSDHPGV + + / +
174-67 3-30 4-23 3 6 2 DLTTVDPSYYYYYGMDV DLTTVDPSYYYYYGMDV κ 1-6 1 0 LQDYNYPWT LQDYNYPWT / + / /
174-82 5-51 4-23 2 4 19 THDGNFFWDY THGGNFFWDY λ 2-14 1 8 SSYTRTNTVTYV SSYTSSSTLTYV / + / /
174-87 3-48 6-13 2 4 1 VGRTSPLYSSSWYGFDY VGRTSPLYSSSWYGFDY κ 3-20 3 0 QQYGSSPFT QQYGSSPFT / + / /
174-119 3-48 2-2 2 4 7 GGYCTSTSCHEPLFGVVMTIPRYFDY GGYCSSTSCHEPLFGVVMTIPRYFDY κ 3-20 5 2 QQYGSSPT QQYGSSPT / / / /
174-130 4-31 5-12 2 4 1 EGVYSAYPSAY EGVYSGYPSDY κ 3-11 3 1 QQRSNWPSFT QQRSNWPSFT + + / /
174-133 1-69 6-13 3 6 21 GIVAADYYGMDV GIVAADYYGMDV κ 2-28 2 4 MQSLQTSFT MQALQTSYT / / / /
174-156 4-39 2-2 2 4 14 RRQRGPDCSSTSCYFDY RRQRGPDCSSTSCYFDY κ 1-5 1 4 QHYDDFA QQYNSYA / / / /
174-174 4-39 4-17 2 5 13 REDYGDYGWFDS REDYGDYGWFDS λ 2-23 3 10 CSYAGRSIM CSYAGSSTM / + / /
175-29 5-51 7-27 3 4 29 LPLTGGACDY LPLTGGACDY κ 3-15 1 14 QQYNKWWT QQYNNWWT + + / /
175-77 3-23 6-19 3 4 13 PASVAGQGGVDY PASVAGQGGVDY κ 1-5 1 9 QQYNTYFQWT QQYNSYSQWT + / / /
175-107 3-7 1-20/7 3 2 20 TARIAGTGGGYFDV TARITGTGGWYFDL κ 1-5 2 13 QQYKSYT QQYNSYT / + / +
175-128 3-23 3-10 3 4 36 DGRRGFLRLVDYLDS DGRRGVLRLVDYFDY κ 2-28 1 12 MQALQTPPT MQALQTPPT / + + +
175-140 4-59 6-19 3 5 18 DRAVAAMYNWVDL DRAVAAMYNWFDS κ 1D-43 4 24 HQYYGTPLT QQYYSTPLT + + + +
175-162 3-33 2-2 3 4 26 GQWGNWRENAVARHYYFDF GQWGNWRDIVVARHYYFDY κ 1-5 1 16 QQYNSSSPT QQYNSYSPT / + / /
175-165 3-23 5-18/5 1 3 10 DPPRWMQLWTTDAFDI DPPRWIQLWTTDAFDV λ 1-44 1 2 ATWDDSLNGRV AAWDDSLNGRV / / / +
175-250 1-2 1-26 3 4 22 DRAIVGAANDFDY DRAIVGAANYFDY κ 3-20 1 8 QQCGSSPT QQYGSSPT / / / /
175-264 3-33 6-19 2 1 14 DGGAYSSGWYPQH DGGAYSSGWYPQH κ 3-15 2 11 QQYNVRPYT QQYNNWPYT + + / /
175-276 1-24 3-10 3 5 22 PYFSTSGSLGDLFDP PYYYGSGSLGDLFDS κ 2-40 1 14 KQRLDGVT MQRIDGVT / + / /
175-277 3-21 6-19/13 3 6 3 PVTPGIALYGVDV PVTPGIALYGMDV κ 1-5 2 3 QQYNSDST QQYNSYST / / / /
175-295 3-9 6-13 2 4 3 GRLRSSTWGYFDY GRLRSSSWGYFDY λ 2-23 3 3 CSYAGSSTWV CSYAGSSTWV / + / /  
reverted amino acids in CDR3s are in bold; RF, reading frame; V-Mut., number of V gene mutations from FWR1 to CDR2, inclusively; mut, mutated 
antibody; rev, reverted antibody; +, reactive in ELISA/IFA; /, non-reactive in ELISA/IFA; poly, polyreactive to ss/dsDNA, LPS, and insulin; HEp2, reac-
tive in HEp2 ELISA and/or IFA 
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Table 12: List of standard primers 
Forward 
Primer 
5' - 3' sequence 
5’ L-VH 1 ACAGGTGCCCACTCCCAGGTGCAG 
5’ L-VH 3 AAGGTGTCCAGTGTGARGTGCAG 
5’ L-VH 4/6 CCCAGATGGGTCCTGTCCCAGGTGCAG 
5’ L-VH 5 CAAGGAGTCTGTTCCGAGGTGCAG 
5’ AgeI VH1 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG 
5’ AgeI VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG 
5’ AgeI VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG 
5’ AgeI VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG 
5’ AgeI VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG 
5’ AgeI VH 4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG 
5’ AgeI VH 1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG 
5’ AgeI VH 1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG 
5’ AgeI VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG 
5’ AgeI VH 3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG 
5’ AgeI VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG 
5’ AgeI VH 6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG 
5’ L Vκ 1/2 ATGAGGSTCCCYGCTCAGCTGCTGG 
5’ L Vκ 3 CTCTTCCTCCTGCTACTCTGGCTCCCAG 
5’ L Vκ 4 ATTTCTCTGTTGCTCTGGATCTCTG 
5’ Pan Vκ ATGACCCAGWCTCCABYCWCCCTG 
5’ AgeI Vκ 1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC 
5’ AgeI Vκ 1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT 
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5’ AgeI Vκ 1D-
43 
CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC 
5’ AgeI Vκ 2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC 
5’ AgeI Vκ 2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
5’ AgeI Vκ 2-30 CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC 
5’ Age Vκ 3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC 
5’ Age Vκ 3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC 
5’ Age Vκ 3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT 
5’ Age Vκ 4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC 
5’ L Vλ 1 GGTCCTGGGCCCAGTCTGTGCTG 
5’ L Vλ 2 GGTCCTGGGCCCAGTCTGCCCTG 
5’ L Vλ 3 GCTCTGTGACCTCCTATGAGCTG 
5’ L Vλ 4/5 GGTCTCTCTCSCAGCYTGTGCTG 
5’ L Vλ 6 GTTCTTGGGCCAATTTTATGCTG 
5’ L Vλ 7 GGTCCAATTCYCAGGCTGTGGTG 
5’ L Vλ 8 GAGTGGATTCTCAGACTGTGGTG 
5’ AgeI Vλ 1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG 
5’ AgeI Vλ 2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG 
5’ AgeI Vλ 3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG 
5’ AgeI Vλ 4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA 
5’ AgeI Vλ 6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG 
5’ AgeI Vλ 7/8 CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG 
5’ Ab sense GCTTCGTTAGAACGCGGCTAC 
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Reverse Primer 5' - 3' sequence 
3’ Cγ CH1 GGAAGGTGTGCACGCCGCTGGTC 
3’ IgG (internal) GTTCGGGGAAGTAGTCCTTGAC 
3’ SalI JH 1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG 
3’ SalI JH 3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG 
3’ SalI JH 6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG 
3’ Cκ 543 GTTTCTCGTAGTCTGCTTTGCTCA 
3’ Cκ 494 GTGCTGTCCTTGCTGTCCTGCT 
3’ BsiWI Jκ 1/4 GCCACCGTACGTTTGATYTCCACCTTGGTC 
3’ BsiWI Jκ 2 GCCACCGTACGTTTGATCTCCAGCTTGGTC 
3’ BsiWI Jκ 3 GCCACCGTACGTTTGATATCCACTTTGGTC 
3’ BsiWI Jκ 5 GCCACCGTACGTTTAATCTCCAGTCGTGTC 
3’ Cλ CACCAGTGTGGCCTTGTTGGCTTG 
3’ XhoI Cλ CTCCTCACTCGAGGGYGGGAACAGAGTG 
Restriction sites are underlined 
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Supplemental materials 
Antibodies and ELISA reagents 
ELISA capture antibody  
goat anti-human IgG, Fcγ-specific Jackson ImmunoResearch Labotarories 
Suffolk, Great Britain 
 
ELISA secondary antibody 
 
Anti-human IgG, Fcγ (HRP) goat Jackson ImmunoResearch Labotarories 
Suffolk, Great Britain 
 
ELISA standard and control antibodies 
 
Human IgG1, kappa Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
ED38 (high positive polyreactive Ig) Meffre, 2004 
JB40 (low positive polyreactive Ig) 
mGO53 (non positive polyreactive Ig) 
Wardemann, 2003 
 
FACS 
 
anti-human CD19 (APC) Invitrogen Co 
Carslbad, CA, USA 
anti-human IgG (Biotin) Invitrogen Co 
Carslbad, CA, USA 
anti-human CD27 (FITC) Invitrogen Co 
Carslbad, CA, USA 
anti human CD38 (PE) Invitrogen Co 
Carslbad, CA, USA 
Streptavidin (PECy7) Invitrogen Co 
Carslbad, CA, USA 
 
Antigens for ELISA 
 
DNA sodium salt from salmon testes Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Insulin solution, human Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
LPS, E.coli 055:B5 Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
 
ELISA plates, pre-coated 
 
QUANTA LiteTM ANA ELISA INOVA Diagnostics Inc. 
San Diego, CA, USA 
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Anti-Ro ORGENTEC Diagnostika GmbH 
Mainz, Germany 
Anti-La ORGENTEC Diagnostika GmbH 
Mainz, Germany 
 
Bacteria and vectors 
E. coli DH10B Clontech, 
Paolo Alto, CA, USA 
Vectors  
(with constant regions of IgH, Igκ and Igλ chain)  
Kind gift of Dr. J. Ravetch 
Rockefeller University 
1230 York Avenue 
New York, NY 10021, USA 
 
Cell line 
HEK 293T Invitrogen GmbH 
Karlsruhe, Germany  
 
Chemicals, buffer and solutions 
2x HBSS (HEPES buffered saline solution), pH= 
7,05 
280 mM NaCl 
50 mM HEPES 
10 mM KCl 
12 mM dextrose 
1,5 mM Na2HPO4· 7H20 
50x TAE (Tris Acetate EDTA) buffer 2 M Tris-Base 
0,05 % (v/v) acetic acid 
0,05 M EDTA (pH=8) 
5x loading buffer 60% (w/v) sucrose 
1mM cresol red 
Ammoniumchloride (NH4Cl) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Calciumchloride (CaCl2) Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Chloroquine (C18H26ClN3) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Cresol red (C21H17O5SNa) Acros Organics 
Geel, Belgium 
Dextrose (C6H12O6· H20) Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
DTT (Dithiothreitol) Invitrogen GmbH 
Karlsruhe, Germany 
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EDTA (C10H14N2Na2O8· 2H2O, ethylendiamine 
tetraacetic acid) 
Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
ELISA blocking solution 1x PBS 
0,05 % (v/v) Tween® 20 
1 mM EDTA 
Ficoll- Paque PLUSTM GE Healthcare Bio-Sciences AB, Uppsala, Sweden 
Fluoromount-G SouthernBiotech Birmingham, AL, USA 
GIBCO™ 10x PBS  Invitrogen GmbH 
Karlsruhe, Germany 
Glycerol (C3H8O3) Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Glycine (C2H5NO2) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
HEPES (C8H18N2O4S, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Igepal CA-630 Sigma Aldrich 
LB-Agar Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
LB- Medium Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Lysis buffer  0.01 M DTT 
8U RNasin 
4U Prime RNase Inhibitor  
in 0.5x nuclease free PBS 
Potassium bicarbonate (KHCO3) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Potassium chloride (KCl) Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Potassium phosphate (KH2PO4) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
RosetteSep® Stemcell Technologies Inc., 
Vancouver, BC, Canada 
Sodium azide (NaN3) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Sodium chloride (NaCl) Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Sodium phosphate (NaH2PO4· 7H2O) Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Sucrose (C12H22O11) Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Terrific-Broth Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
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Trizma® base Sigma Aldrich Chemie GmbH 
Steinheim, Germany 
Tween® 20 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
  
 
Reverse transcription  
RHP mix  0.016 % NP-40 
1 µl 10 % DTT 
165 ng RHP 
3 U PRIME RNase Inhibitor 
RT mix  2.15x RT-Puffer 
14.3 mM DTT 
1.8 mM dNTPs each 
50 U Superscript III 
4 U RNasin 
3 U PRIME RNase Inhibitor 
 
Kits employed 
HiSpeed® Plasmid Maxi Kit Qiagen GmbH 
Hilden, Germany 
HRP Substrate Kit Bio-Rad Laboratories GmbH, 
München, Germany 
QIAPrep® Spin Miniprep Kit Qiagen GmbH 
Hilden, Germany 
QIAquick® gel extraction Kit Qiagen GmbH 
Hilden, Germany 
QIAvac® 96 DNA purification Kit Qiagen GmbH 
Hilden, Germany 
Immunofluorescence assay BIOS GmbH, 
München, Germany 
INNO-LIA ANA Update Innogenetics Biologicals, 
Gent, Belgium 
 
Enzymes and additives 
 
Restriction enzymes  
AgeI, BsiWI, SalI, Xhol New England Biolabs GmbH Frankfurt am Main, Germany 
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RT (Reverse transcription)- and PCR 
10x PCR buffer Qiagen GmbH Hilden, Germany 
5x first strand buffer Invitrogen GmbH Karlsruhe, Germany 
100 mM dNTP Set (dATP, dCTP, dGTP, dTTP), 
PCR grade 
Invitrogen GmbH 
Karlsruhe, Germany 
HotStar Taq DNA Polymerase Qiagen GmbH Hilden, Germany 
Nonidet P40 Sigma Aldrich Chemie GmbH Steinheim, Germany 
Nuclease-free water Eppendorf AG Hamburg, Germany 
RNase Inhibitor 5 PRIME Eppendorf AG Hamburg, Germany 
RNasin® Promega GmbH Mannheim, Germany 
Seakem® LE Agarose Cambrex Bio Science Rockland, Inc. Rockland, ME, USA 
SuperscriptTM III RT Invitrogen GmbH Karlsruhe, Germany 
Taq DNA Polymerase Roche Diagnostics GmbH Mannheim, Germany 
 
Cloning  
T4 DNA Ligase New England Biolabs GmbH Frankfurt am Main, Germany 
 
ELISA  
1-StepTM ABTS Pierce Biotechnology, Inc. Rockford, IL, USA 
Horseradish Peroxidase Substrate Kit BIO-RAD Laboratories GmbH Munich, Germany 
 
Antibody purification  
Protein G Sepharose™ 4 Fast Flow GE Healthcare Bio-Sciences AB Uppsala, Sweden 
Bio-Spin chromatography columns BIO-RAD Laboratories GmbH Munich, Germany 
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Equipment and lab material 
1.5 ml reaction tubes SARSTEDT AG & Co. Nümbrecht, Germany 
96well Multiply- PCR plate SARSTEDT AG & Co. Nümbrecht, Germany 
96well PCR plate Eppendorf AG Hamburg, Germany 
Alpha Imager  Alpha Innotech Corporation San Leandro, CA, USA 
Axioplan 2 imaging fluorescence microscope Carl Zeiss MicroImaging GmbH, Jena, Germany 
  
BioPhotometer Eppendorf AG Hamburg, Germany 
BioSpin® chromatography columns Bio-Rad Laboratories GmbH, München, Germany 
Cell culture dishes (150 mm) Falcon, Becton Dickinson GmbH Heidelberg, Germany 
Cellstar® sterile serological pipettes  
2 ml, 5 ml, 10 ml, 25 ml, 50 ml 
Greiner Bio-One  
Frickenhausen, Germany 
Centrifuge 5180R (Rotor A-4-81) 
Used for reaction tubes larger than 2 ml 
Eppendorf AG 
Hamburg, Germany 
Centrifuge 5417R (Rotor F-45-30-11) 
Used for reaction tubes up to 2 ml 
Eppendorf AG 
Hamburg, Germany 
CO2 incubator CB210 
Binder GmbH 
Tuttlingen, Germany 
Clean bench HERAsafe KS12 Thermo Electron Corp. Langenbold, Germany 
Domed 12-Cap Strips (PCR Tubes Strips) Bio-Rad Laboratories GmbH, München, Germany 
ELISA high binding microtiter plates  
(96well,flat bottom) 
Costar, Corning B.V 
Schiphol-Rijk, Netherlands 
FACSVantage BD Biosciences Franklin Lakes, NJ, USA 
Incubator BE 600 Memmert GmbH + Co.KG, Schwabach, Germany 
Inoculation loops, inoculation needles 
(polystyrene) 
Nunc GmbH & Co. KG 
Wiesbaden, Germany 
Mastercycler® ep gradient Eppendorf AG Hamburg, Germany 
Microseal 'F' Film Bio-Rad Laboratories GmbH, München, Germany 
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Microwave  Panasonic Germany Hamburg, Germany 
Multichannel Pipet-Lite® with LTS 
2…20 µl, 20…200 µl, 100…1200 µl 
Rainin Instrument, LLC 
Woburn, MA, USA 
Multipette plus Eppendorf AG Hamburg, Germany 
Parafilm Pechiney Platic Packaging, Chicago, IL, USA 
Petri dishes (100 mm) Greiner Bio-One  Frickenhausen, Germany 
Pipetboy acu INTEGRA Biosciences GmbH Fernwald, Germany 
Pipet-Lite® with LTS 
0.1…2 µl, 2…20 µl, 20…200 µl, 100…1000 µl 
Rainin Instrument, LLC 
Woburn, MA, USA 
Polypropylene tubes (15 ml, 50 ml) SARSTEDT AG & Co. Nümbrecht, Germany 
Rotator drive STR4, Stuart scientific Keison Products Essex, England 
SpectraMax 190 Microplate Reader Molecular Devices Corporation Sunnyvale, CA, USA 
Thermomixer comfort Eppendorf AG Hamburg, Germany 
Vaccu-Pette/96 Scienceware/Bel-Art Pequannock, NJ, USA 
Vortex genie 2 Scientific Industries, Inc. Bohemia, NY, USA 
Water bath with thermostat JULABO Labortechnik GmbH Seelbach, Germany  
Water bath GFL 1008 GFL Gesellschaft für Labortechnik Burgwedel, Germany 
 
Media and supplements for bacterial and tissue culture 
Ampicillin Sigma Aldrich Chemie GmbH Steinheim, Germany 
GIBCO™ Antibiotic-Antimycotic (100X)  Invitrogen GmbH Karlsruhe, Germany 
GIBCO™ DMEM (Dulbecco's Modified Eagle 
Medium) 
Invitrogen GmbH 
Karlsruhe, Germany 
GIBCO™ L-Glutamine Invitrogen GmbH Karlsruhe, Germany 
GIBCO™ Trypsin Invitrogen GmbH Karlsruhe, Germany 
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GIBCO™ FBS (fetal bovine serum) Invitrogen GmbH Karlsruhe, Germany 
LB-Medium Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
LB-Agar Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Nutridoma-SP Roche Diagnostics GmbH Mannheim, Germany 
Terrific-Broth-Medium Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 
Nucleotides and nucleic acids 
100 bp DNA Ladder New England Biolabs GmbH Frankfurt am Main, Germany 
1 kb DNA Ladder New England Biolabs GmbH Frankfurt am Main, Germany 
dNTPs (Desoxyribonucleotidyl Triphosphate) Invitrogen GmbH Karlsruhe, Germany 
Oligonucleotides MWG-BIOTECH AG, Ebersberg, Germany 
Random Hexamer Primer pd(N)6 Roche Diagnostics GmbH Mannheim, Germany 
 
Software 
Adobe Illustrator CS3 Adobe Systems GmbH München, Germany 
GraphPad Prism 5 GraphPad Software, Inc. San Diego, CA, USA 
SeqMan™ II DNASTAR, Inc. Madison, WI, USA 
SoftMax Pro 5 Molecular Devices GmbH Ismaning, Germany 
 
Internet sources 
IMGT http://imgt.cines.fr/ 
IgBlast http://www.ncbi.nlm.nih.gov/igblast/ 
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